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Summary
Positron emission tomography (PET) is an in vivo tracer kinetic technique. This
thesis is concerned with the analysis of data derived from PET studies in humans.
There are two related themes in the thesis. Firstly, the derivation of mathemati-
cal models with particular reference to the modelling of radiolabelled metabolite
formation in plasma and tissue. Secondly, the identifiability of model structures
is examined, and a method for the reparameterisation of unidentifiable models
is derived. Compartmental models describing the accumulation of radiolabelled
metabolites in plasma following the intravenous administration of ["C]flumazenil
and [11 C]diprenorphine are presented. A theorem is presented which gives condi-
tions for a unique solution to the spectral analysis approach (a kinetic modelling
technique used in PET which is based on the a priori definition of a large set of ba-
sis functions). Mathematical techniques are presented for the analysis of expired
a major labelled metabolite in many PET studies. This range of ana-
lytical and modelling techniques is then applied to the analysis of ["C]thymidine
scans. [11 Cl Thymidine is a PET tracer being developed for the measure of tumour
proliferation in cancer patients. The techniques developed in the thesis allow for
the removal of the confounding labelled metabolite signals from both plasma and
tissue data.
Chapter 1
Introduction
This thesis will consider the mathematical modelling of biomedical systems in the
field of positron emission tomography (PET). PET is an in vivo tracer technique
which allows the measurement of tissue functions in humans and as such is a
unique clinical research tool. The method employs radiolabelled compounds to
study the kinetics of selected biochemical and pharmacological functions. The
technique relies on the quantitative modelling of the kinetic behaviour of the
injected tracer and therefore a substantial part of PET research considers mathe-
matical models and their application. Important topics include model formulation,
model selection, identifiability and parameter estimation techniques. PET relies
heavily on mathematical methods, not just for modelling but also for tomographic
reconstruction, image analysis and image realignment. For quantification of tissue
function (with tracer kinetic modelling) input and output data are a prerequisite.
These data are obtained by blood sampling from the PET tomograph respectively.
These data allow for the creation of plasma and tissue time courses of the con-
centration of tracer. A major problem in PET is the metabolism of the injected
tracer. Consequently, the measured data is usually contaminated by the presence
of labelled metabolites. Techniques for the correction of the plasma and tissue
data are essential such that accurate model parameters can be estimated. This
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thesis is concerned with the development of mathematical models for both plasma
and tissue data and their application to PET.
The three inter-related themes to this thesis will be identifiability analysis, tracer
kinetic modelling and metabolite contamination of the data. An outline of the the-
sis is illustrated in Figure (1.1). Following the two introductory Chapters (2 and
[	 Chapter 1
LIntroduction
Chapter 2
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Chapter 3
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Chapter 4
Unidentifiable Models
and Reparameterisation
Chapter 8	 Chapter 9
Carbon Dioxide
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(	 Chapter 10
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Figure 1.1: Thesis Structure
23) on PET and modelling Chapter 4 considers identifiability and unidentifiable
systems. The process of identifiability allows for the theoretical investigation of
model structures to determine whether they are robust when utilised for parameter
estimation from input output data. A method for reparameterising unidentifiable
systems is investigated and this is applied to a model for the metabolite correction
of plasma input functions in Chapter 5. The theme of tracer kinetic modelling is
apparent throughout the thesis, a review of available techniques is presented in
Chapter 3 and one method (spectral analysis) is examined in detail in Chapter 6
with particular reference to the uniqueness of the solution. Applications of com-
partmental modelling and spectral analysis as tools for the investigation of tracer
kinetics are considered in Chapters 5, 8 and 9. The theme of metabolite correc-
tion via the application of mathematical mddels will be considered in Chapters
5, 8 and 9 with reference to the tracers [' 1 C]flumazenil, [11 C]diprenorphine and
[11C] thymidine. A conclusion will be presented in Chapter 10 together with future
work arising from this thesis.
Chapter 2
Positron Emission Tomography
2.1 Overview
PET is a unique tool for studying pharmacokinetic, physiological and biochem-
ical processes in vivo iii humans. The ability of PET to acquire non-invasive
functional images makes it an unprecedented tool for the study of neurology, car-
diology, and oncology. Its principle roles include the in vivo measurement of blood
flow, metabolism and receptor concentrations [1]. PET has been used widely by
neurologists with respect to brain mapping of cognitive function [2] and the study
of neurological diseases such as Parkinson's disease [3], epilepsy and Alzheimer's
[4]. Cardiologists use PET to measure myocardial blood flow, metabolism and
receptor concentrations [5] [6]. Oncologists are now increasingly using PET to
investigate the biochemistry of cancers and their response to anti-cancer agents
and other forms of therapy [7] [8] [9]. Psychiatrists use PET to study the neu-
roreceptor systems in brain disorders such as depression and schizophrenia [10].
The technique is making use of an increasing variety of radiolabelled tracers. The
fundamental mechanism of PET is the emission of a positron from an unstable
nucleus and the consequent annihilation with a nearby electron. This annihilation
produces two almost collinear gamma rays of 5llkeV each which can be detected
in coincidence on either side of the active volume. The localisation of the an-
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nihilation allows the tracers spatio-temporal distribution to be determined. In
addition, the detection of the two gamma photons as opposed to single photons
as in conventional nuclear medicine facilitates the determination of absolute tracer
concentrations [11]. This enables functional parameters to be accurately derived
and increases detection sensitivity.
2.2 Tracers
The use of positron emitters that are isotopes of commonly occurring elements
facilitates the use of many different tracer compounds of biological significance
[12]. A tracer should not disturb the underlying biological system, that is the
amount of non-radioactive material is required to be small. The compounds are
administered in minute quantities and this radiation dose corresponds to approx-
imately one year's normal background radiation. The tracers are produced by
chemical reactions involving one of the several common isotopes. Isotopes that
are frequently used as positron emitters are listed with their physical half-lives in
Table (2.1). The short half-lives of the isotopes reduces the dose of radiation to
the subject and allow for repeat studies to be performed.
0_Radionuclide Half-Life (mins)
11 Carbon	 20.4
13Nitrogen	 9.96
'5 Oxygen	 2.05
18Fluorine	 109.7
Table 2.1: Half-lives of commonly used isotopes
These radioisotopes are produced with a particle accelerator (a cyclotron). The
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cyclotron produces the isotopes by accelerating a beam of charged atomic particles
(protons, alpha particles or deutrons) under the influence of electric and magnetic
fields. The beam irradiates a target (solid, liquid or gas) causing a nuclear reaction
to take place, producing the raw radioisotope. The short physical half-lives of
positron emitting tracers necessitates the presence of an on-site cyclotron (or
nearby - i.e. .' 1-2 hours journey for ' 8F is reasonable) for their production. The
radioisotope then undergoes chemical synthesis producing the required compound
incorporating a positron emitting label. High initial yields of positron emitters and
fast subsequent synthesis produce tracers with high specific activity. The specific
activity of a compound is defined to be the ratio of radioactivity to mass of the
compound. This must be high to ensure that the concentrations of the unlabelled
compound do not interfere pharmacologically with the in vivo measurement of
the radioligand kinetics [13]. In essence, a high specific activity compound meets
the criterion for an ideal tracer.
2.3 Physical Principles
Positron emission involves the decay of certain proton-rich nuclides by the emis-
sion of a positron, a positively charged electron, to leave an extra neutron and
one less proton [14]. The total kinetic energy released by this process is shared
between the pdsitron and a neutrally charged particle, a neutrino. The compet-
ing decay scheme for nuclides having an extra proton is capture of an inner shell
electron.
p - n + /3 + v (Positron Emission)
p + e -* n + v	 (Electron Capture)
(2.1)
On emission, the positron loses kinetic energy via collisions with electrons from
surrounding atoms until its energy is about a few electron volts, at which point its
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collision with an electron results in annihilation of the electron pair and conversion
of their total mass to energy (via Einstein's equation the energy released is E =
2m0 c2 ). Conservation of energy yields two photons each of energy 5llkeV which
are emitted in close to opposite directions, the small non-collinearity arising from
possible non-zero momentum on annihilation.
An emitted positron travels a short distance (up to a few mm in tissue) until it
annihilates with a stationary electron and this introduces a spatial blur in the
distribution of the compound. This and the non-collinearity define the intrinsic
maximum resolution that one can achieve with a PET system.
2.4 Detection of Gamma Rays
Positron
________ 
Ganuna
Detector	 Detector
Electron
Coincidence
Figure 2.1: Scheme of basic PET principle
The principle behind the gamma ray detection involves the use of scintillation crys-
tals [11]. When a gamma ray interacts with a crystal, such as bismuth germanate
(BGO), the motion energy is converted into light which is then transformed into
an amplified electrical pulse by a photo multiplier tube (PMT) attached to the
rear of the crystal. The PMTs are wired up to electronic hardware that allows
for rapid recording of the detected events. Using a pair of gamma detectors, the
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occurrence of an annihilation can be ascertained (Figure (2.1)). By connecting a
pair of gamma detectors in a coincidence circuit the occurrence of single nuclear
disintegrations can be accounted for. The coincidence unit behaves similarly to a
logical AND gate, if both input pulses are registered within a small time window
(coincidence window < 20 ns) then a coincidence count or event is recorded.
2.5 PET Camera
A commercial PET tomograph [15] [16] usually consists of multiple crystal PMT
modules, or detector blocks arranged in rings surrounding the subject which are
connected up to detect coincidences, as in Figure (2.2). The tomograph localises
Figure 2.2: PET tomograph
disintegrations by means of electronic collimation. When two gamma rays are
detected within the coincidence time window an event is recorded. The spatial
position of the disintegration can be localised to a straight line joining the two
AB
Angles
(Views)
Projections
2.6 Sinogram	 8
coincident detectors, termed a line of response (LOR). During a PET scan events
are recorded between the currently many millions of detector pairs which rep-
resent line integrals or projections at different angles around the subject. The
raw data set is termed a sinogram (a matrix of angle vs. projection LOR). Us-
ing tomographic reconstruction techniques an image of the tracer distribution
can be obtained (localisation is effected by the intersection of many LOR's pass-
ing through a particular source location). There are two favoured reconstruction
techniques; Filtered back projection [17] and iterative reconstruction [18]. The
spatial resolution is primarily determined by the dimensions of the detector ele-
ments and can be as high as 3mm for modern scanners. The temporal resolution
or frame rate that can be used is limited by the radioactivity in the field of view
and the decay of the radionuclide.
2.6 Sinogram
Each disintegration event is recorded by coincidence processing hardware and
stored in a 2-D matrix, or sinogram [14], as in Figure (2.3). A sinogram is an
Tomograph Geometry 	 Sinogram
Figure 2.3: Composition of a sinogram
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array that consists of the coincidence LOR's reformatted into sets of parallel
projections at different angles or views. The value in each element of the sinogram
is the number of counts for each LOR, i.e. a line integral.
2.7 Mispositioning of Events
There are three types of coincidence events recorded, see Figure (2.4); i) a true
event, from an annihilation lying within the detection channel, ii) a random event,
two uncorrelated photons from separate annihilations detected within the coinci-
dence time window, iii) a scattered event, when one or both gamma ray interact
with an atomic electron in the medium the direction of the gamma ray changes
as a result of losing some energy (by the principle of conservation of momentum)
[14].
Scattered Event
Gamma	 Gamma
Detector_	
rue Event	
DetectoP
Random Events
Coincidence
Circuit
Figure 2.4: Possible coincidence detections
The raw counts measured by a PET camera are defined by the following equation;
Cmeasured = Cirue + Crandom + Cscatter
	
(2.2)
So to obtain the true counts the measured signal must be corrected for randoms
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and scatter.
Randoms are normally measured by delaying the signal on one of the detector
pairs so that just randoms are recorded, i.e. all the true coincidences have been
removed from the signal. Alternatively one can use Crandom = 2rN 2 N where 2r
is the length of the coincidence time window and N and N are the singles count
rates from the two coincident detectors. However, the width of the time window
needs to be known very accurately for such a technique to be used.
The counts in a detector channel must be corrected for counts lost due to scatter
out of the LOR and in addition for photons absorbed by the medium.
The following equation defines the number of photons lost due to the traversal
through a medium.
I = Io&
	 (2.3)
where I = number of photons after traversal, 10 = number of photons before
traversal, x = the total thickness of the medium, ji = the attenuation coefficient
of the medium.
Unlike single photon emitters the detection of the two photons in PET means
the attenuation is not dependent on the depth of the source in the medium and
only depends on the thickness of the medium. This greatly simplifies the process
of attenuation correction. A transmission scan is acquired with the patient in
the scanner, and involves the measurement of attenuation by utilising an external
long-lived positron emitting source (normally 68 Ge). A blank scan is similarly
acquired but without the patient in the scanner. The ratio of blank scan to
transmission scan is then used as the attenuation correction. There are various
methods for scatter correction such as convolution subtraction or the dual energy
window approach [19] {20].The accurate correction for attenuation and scatter is
essential for the production of quantitative functional images.
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2.8 2D and 3D Acquisition
Data can be collected in. two different geometries; In 2-D, events within narrow
axial acceptance angles are recorded, these being restricted by the presence of
inter-ring lead or tungsten septa which are used to remove scatter and randoms.
In 3-D, septa are removed and any detector ring can be in coincidence with any
other ring (unlimited acceptance angle) [21]. 3-D mode is more sensitive (more
events are recorded per activity) and this allows for a reduction in the amount
of radioactivity administered to a subject. The reduction in dose is becoming
increasingly important as the advisory boards are lowering the allowable doses of
activity.
2.9 Resolution of PET
The data collected from the scanner is a temporal and spatial distribution of
the tracers' concentration. For each measured time frame of data a discretised
volume of the tracers concentration is obtained. The maximal spatial resolution
of any PET system is limited, this results from a positron travelling up to a few
mm before annihilating with an electron and also non-collinearity (the bigger the
detector ring the bigger the blur due to this) [11]. However in practise the size of
the detector elements is the limiting factor, although modern technology means
that PET cameras are now approaching their maximal spatial resolution.
2.10 Quantification
Studies are performed where the activity concentration in a test cylinder or phan-
tom, can be determined by placing samples of the activity in a calibrated sodium
iodide well counter [11]. This enables accurate factors to be obtained which
produce cross calibration between the PET camera and the well counter, i.e.
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Counts/voxel Ci/ml. The BGO blood detection system (see below) is also
calibrated with the same well counter (counts/mi -* aCi/ml), and this facili-
tates the calculation of a linear factor which calibrates the PET data to the blood
data. To achieve quantitative measures of tissue function it is necessary to acquire
several associated measurements. In addition to normalisation (for detector ineffi-
ciencies and geometrical effects) and calibration data for the scanner the following
measures are required;
. Spatio-temporal measure of concentration of tracer in tissue
. Attenuation data
. Concentration of the label in blood
. Distribution of label between plasma and whole blood
. Metabolite measurements of the parent tracer in plasma
During a PET scan, aliquots of blood are drawn from the subject and counted in
the well counter which enables a direct quantification of the activity in the PET
images.
2.11 Blood Sampling
To acquire quantitative information from the tissue of interest it is essential to
know the temporal concentration of the compound in plasma. The most robust
method of acquiring these data involves utilising continuous on-line blood sam-
pling throughout the scan [22]. The subject's radial artery is cannulated and a
pump is used to withdraw blood at a constant rate through a BGO detector block
which continuously measures the activity in the blood, see Figure (2.5). Discrete
samples of blood are taken for calibration, plasma to whole blood calculations and
IPump
)
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Waste Blood
Figure 2.5: Blood sampling system
for metabolite analysis. The tubing passes through the BGO detector block in
the shape of a hairpin, this maximises the volume of blood which can be detected,
increasing sensitivity.
Both lO22keV "sum" coincidences and 5llkeV "singles" events are recorded giving
extra sensitivity (heavy lead shielding of the equipment is employed to minimise
background counts). The continuous sampling contains a series of "blips" in the
data due to the flushing of the line with saline which ensures that the blood does
not clot in the tubing. The background count rate needs to be removed from the
data. The true background count rate is related to the activity surrounding the
detector and theoretically this will depend on the activity in the subject, however
with suitable lead shielding this problem can be minimised.
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2.12 Tracer Metabolism
One of the most challenging problems in PET results from any metabolism of the
injected compound. Metabolism refers to the degradation of the parent compound
into various smaller component parts. As a consequence of the parents positron
label some of it's associated metabolites will have an inherent label as well [13].
These metabolites which also produce annihilation events confound the signal of
the compound of interest. When metabolism of a compound occurs mathemat-
ical models of the metabolism are necessary to account for the contribution of
metabolites.
2.13 Metabolite Analysis
To ascertain the contribution of metabolites to the plasma input function discrete
plasma samples are analysed for their parent and metabolite composition. Various
methods for the analysis of samples exist of which the two most common are
High Pressure Liquid Chromotography (HPLC) and Thin Layer Chromotography
(TLC) [23] [24].
2.14 Summary
This chapter has explained the principles and methodology in obtaining quanti-
tative tracer concentrations in tissues of interest and plasma. The next chapter
considers how these data may be transformed using mathematical models to pro-
vide physiological "functional" parameters.
Chapter 3
Modelling and Identifiability
3.1 Overview
This chapter reviews the topics of modelling and identifiability which form the
two main aspects of this thesis. The two topics are intrinsically linked. A model
defines some form or structure with which parameters are associated. Parameter
values are obtained so that the model output matches the measured data as closely
as possible. Identifiability refers to the process of assessing whether it is possible
to obtain unique values for these parameters from experimental data.
3.2 Modelling
Mathematical modelling techniques are applied to PET data in order to produce
relevant functional parameters of the body's physiology, biochemistry and phar-
macology. The raw data often gives little insight into the parameters of interest
and this is why it is necessary to use tracer modelling techniques so as to ex-
tract a more comprehensive description of the underlying physiological processes.
Hence, rather than just recording the integrated radioactivity counts, it is pos-
sible to derive various important functional parameters such as the distribution
volume (VD), blood flow, concentrations of binding sites, binding affinities and
15
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mean residence times, etc [25].
3.2.1 Introduction
The information obtained from a PET scan is a temporal and spatial measure
of the tracer concentration in the tissue of interest. A simultaneous measure of
the tracer concentration in plasma can be obtained and the acquisition of both
plasma and tissue time courses allows for the investigation of plasma to tissue
transfer of the compound, as in Figure (3.1). The frame durations for which
Plasma(t)
'1'
Blood Sampling
Physiological
Transfer Function
Tissue -.
Tissue(t)
1'
PET Scanner
Tissue(t) = Physiological Model® Plasma(t)
Figure 3.1: Modelling scheme
tissue data are collected are variable and a typical protocol would consist of short,
initial time frames (typically 5-60 secs) to characterise the fast, initial stages of
the distribution of the tracer in tissue and longer, later time frames (typically 5-15
mins) to capture the uptake or washout from the tissue. The protocol for data
acquisition should consider the important parameters to be estimated and tailor
the experimental design to maximise the accurate estimation of these parameters
[26] [27].
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3.2.2 Tissue Data
The kinetic data obtained from a PET camera can be either analyzed at the single
pixel level (i.e. at the order of the spatial resolution of the camera - e.g. 6mm
x 6mm x 6mm [15]) or on the basis of a so called region of interest (ROT) which
is taken to mean a larger region defined by the user (e.g. 50 mm x 50 mm x 30
mm). There are advantages to analysis at both levels with a trade-off having to
be made between statistical noise and resolution. Pixel by pixel analysis gives
detailed spatial information, that may be obscured at the ROT level. This allows
for the generation of "functional" or "parametric images", where each pixel in the
image contains the parameter value at that spatial location (it should always be
emphasised that image "pixels" are not statistically independent - i.e. anything
with dimensions < resolution of the camera). However, the data are noisy at the
pixel level compared to the low noise properties of ROT-generated curves, and
the noise levels determine the number of viable parameters that are numerically
identifiable.
An ROT is drawn on a reference image which is usually the integral of the dy-
namic image sequence. The reference image is chosen such that it maximises the
delineation of the structures of interest. The ROT is then applied to the dynamic
image sequence and all pixel values within the ROT are averaged for each time
frame resulting in a complete time activity curve for the ROT.
3.2.3 Plasma Data
The simultaneous measure of continuous on-line blood radioactivity, the plasma
to blood partition, and metabolite analysis of plasma assays allow for the genera-
tion of a plasma metabolite-corrected input function. This provides a continuous
measure of the parent compound's concentration in plasma and this process is
described in more detail in Chapter 5.
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3.3 Modelling Techniques
Typically in PET we are concerned with single-input single-output (SISO) systems
and the system identification problem. There are various different modelling ap-
proaches which can be used to examine the data, ranging from data-led techniques
to ones incorporating more a priori assumptions, or model-led techniques (Figure
(3.2)). The more data-led techniques minimise a priori assumptions and instead
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Figure 3.2: Spectrum of modelling techniques
interrogate the measured data to ascertain the characteristics of the system. An
example of this is principal components analysis (P CA) [28] which considers the
variance-covariance structure of the tissue data. The model-led (or constrained)
techniques utilise knowledge of the underlying system and involve an increased
degree of parameterisation. This corresponds with a loss in the number of degrees
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of freedom in the system which makes them increasingly susceptible to noise. A
model-led technique is exemplified by compartmental analysis and may not be
robust at the pixel level if the model is too complex.
With an increase in model structure, the problems of theoretical and numerical
identifiability become more important. The data-led techniques dictate what can
be identified from the data themselves, whereas the structures of the more model-
led techniques require investigation in order to validate their applicability. Data-
led techniques often fail to fully characterise the parameters of interest, however
they are extensively used as first pass analyses with new tracers when little is
known about the tracer's behaviour. Their important advantage here is that they
make few a priori assumptions.
Model-led techniques, such as compartmental analysis, are far more involved with
processes such as model selection, identifiability, and model validation is required.
Compartmental analyses normally requires a metabolite-corrected plasma input
function to give truly quantitative parameter estimates. If compartmental tech-
niques are successful they provide a greater understanding of the system.
Data-led techniques lend themselves to noise reduction, whereas more structured
models can be more easily related to physiologically interpretable parameters.
3.3.1 Multivariate Based Techniques
Principal Components Analysis
PCA [28] is a technique which extracts the key temporal components from a dy-
namic data set. The method is based on an orthonormal transformation of the
standard coordinate axes. The method is frequently used to obtain components
for the purpose of factor analysis, see below. The number of significant compo-
nents can be assessed by choosing components whose eigenvalues account for a
significant proportion of the variance (typically 70-90%). The method is limited to
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extracting the fundamental components and any small pockets of distinctly differ-
ent behaviour may be ignored. The method of principal components examines the
variance-covariance structure of the data via a linear combination of the original
data. Interpretation of the factors is the difficult and involved part of the process.
The factors obtained often need to be transformed to produce intelligible phys-
iological factors. This is normally performed by a rotation of the factors which
constrains them to be positive (physiologically plausible) [29]). These factors may
then be used as part of a factor analysis [30]
Factor Analysis
Factor analysis is performed by fitting a linear combination of temporal com-
ponents to the tracer time course. The distinct temporal components can be
obtained from time activity curves derived from ROT's, by PCA, or other kinetic
techniques such as cluster analysis. Factor analysis has recently been applied to
cardiac PET data [31] [32].
Cluster Analysis
Cluster analysis is a data-led technique. It attempts to identify clusters of pixels
in feature space (the n-dimensional time activity curves are treated as points in n -
dimensional space) by fitting a small number of multi-normal distributions which
encompass most of the data. The probability of a pixel lying within each of these
clusters may be calculated and this gives the weightings for the contribution of
each identified shape. Cluster analysis has a potential as a segmentation technique
and relies on distinct temporal shapes existing in the data [33].
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3.3.2 Compartmental Based Techniques
With the acquisition of an input function, modelling techniques which propagate
from a compartmental framework can be applied. These methods address the
general modelling problem in PET, that of system identification which involves
identifying a tissue response function from measured input (plasma) and output
(tissue) data.
Spectral Analysis
Spectral analysis was first applied to PET data by Cunningham and Jones [34],
and is a technique which lies in between data-led and model-led techniques. It
assumes that the tissue impulse response function can be constructed from a
sum of nonnegative exponential terms. By taking a discrete spectrum of possible
exponentials (/3 ), which are pre-chosen and fixed, from the fastest (blood effects)
to the slowest (decay of the isotope), the problem can be linearised, i.e.
PET0bS(tk) C(t) ®
	
ae 13t	 (3.1)
given k E 1, 2, ..., N} and the non-negativity constraint a ^ 0 and where,
PETobs(t) : Tissue time course
C(t) : Plasma time course
The problem is then solved using a nonnegative least squares algorithm. By defi-
nition of the impulse response the method is able to characterise both irreversible
and reversible systems with many compartments. Spectral Analysis has been
used at the pixel level to produce functional images [35]. This thesis deals with
a particular aspect of the method (the uniqueness of the solution) that was orig-
inally perceived as a problem [36]. Chapter 6 presents a novel proof which gives
conditions for a unique solution.
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Patlak Analysis
Patlak or graphical approaches [37] [38] [39] were first used by Rutland [40] and
developed in a more theoretical framework by Patlak , and can be used to measure
the irreversible uptake rate of a tracer. The basic method involves a transforma-
tion of the tissue and plasma data.
PETobs(t)	 Cfr)dr 
+ 0 + Vp	(3.2)C(t)	 C(t)
where
PETobs(t) : Tissue time course
C(t)	 Plasma time course
K : Irreversible uptake rate constant
14, : Volume of plasma in sampled tissue region
Vo : Volume of distribution
This relationship approaches linearity after a certain amount of time when the
exchangeable compartments approach a pseudo-equilibrium. The irreversible up-
take rate, K2 , can then be measured by fitting a straight line to the data after
this time. The advantage of this method is that the number of intermediate re-
versible compartments is unimportant and just the overall uptake rate constant
from plasma , into the irreversible compartment is obtained. Logan extended the
graphical approach to consider reversible systems [39].
Weighted Integration
Weighted integration is a technique that was originally developed in PET for
analysis of blood flow and can be applied at the pixel level [41] [42]. The method
requires two or more weighted count rate integrals, depending on the number of
parameters that are to be estimated. The particular advantage of this technique
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is that it can be used during data acquisition, thus providing a reduction in the
size of acquired data sets. The weighted count rate integrals are defined as
= 1T 
w1(t)CpET0b(t)dt (i	 1,.. . , n)	 (3.3)
where
PETobs(t) : Tissue time course
w(t) : Weighting functions
T : Time at the end of the scan
n : Number of distinct integrals
The weighting functions w must be distinct and typical functions include unity,
exponential decay and time [43]. Equation (3.3) can also be defined in terms of
the model parameters,
I = (1 - T) f w1 (t).C(t) 0 IR(t)dt + Vbw(t)Cb(t) (i = 1,.. . , n)	 (3.4)
where
IR(t) : Impulse response function
C(t) : Plasma time course
Cb(t) : Whole blood time course
Vb : Blood volume
The parameter values are then obtained by setting (3.3) and (3.4) equal to each
other and then solving for the parameter values. Weighted integration has been
used to calculate [11 C]flumazenil binding parameters, Bma(receptor concentra-
tion) and Kn(equilibrium dissociation constant), using a single compartment
model and a dual study, steady-state protocol [44]. The method can be extended
to consider the two compartment (3 parameter) model for ['8F]fluorodeoxyglucose
(FDG) producing effective images of K, which represents the irreversible uptake
of FDG and is proportional to the tissues utilisation rate of glucose [43J.
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Linear Compartmental Systems
A system is defined as a complex entity consisting of interacting parts [45]. In
compartmental modelling a complex system is constructed from a series of inter-
acting compartments. Each individual compartment obeys a simple set of rules
and these compartments are combined to form a complex system which describes
the whole biological process. General systems theory has its origins in the 1940's.
A description of compartmental analysis in medicine and biology can be found in
Jacquez [46] . The processes which will be examined will all contain some form
of input to the system and some form of output. Compartmental modelling is
a technique involving a simplification of the underlying physiological processes,
instead taking into account the principal dynamic elements.
Each compartment is considered as a homogeneous well mixed entity with its own
distribution volume. The distribution volume is defined by the ratio at equilibrium
of the concentration of tracer in tissue divided by the concentration in plasma, and
has units of (ml plasma)(ml tissue)'. Compartments can be spatially distinct or
they can denote the same physical space occupied by different chemical species.
The term linear refers to the fact that the rate at which material is transferred
between compartments is linear, that is proportional to the amount of material
in the compartment and hence the transfer rates are called rate constants.
Initially the model may be constructed in terms of interacting compartments which
convey the appropriate biological processes. The compartmental system is then
transcribed into the appropriate system of ordinary linear differential equations.
In compartmental modelling, one derives a set of equations which are obtained
from the theory of conservation of mass. A set of first order ordinary linear
differential equations are obtained.
In the limit, at equilibrium or steady-state, the quantities and concentrations of
the tracer in the compartments remains unchanged.
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There are certain assumptions which a linear compartmental system imposes:-
• the tracer mixes uniformly in each compartment
• the tracer mixes instantaneously in each compartment
• the rate constants between compartments are constant
• the amount of tracer must be very small compared to the system it is to
measure.
The Laplace transform [47] provides a very effective and established method for
solving a set of ordinary linear differential equations.
Nonlinear Compartmental Systems
The rate constants for compartmental systems are not always constant (the rate
may depend on time or a system variable), producing nonlinear compartmental
models. Nonlinear models are more complicated to solve with a general analytical
solution rarely available (Laplace transforms only apply to linear systems) and
numerical methods are normally required. An example of a nonlinear compart-
mental model in PET is a saturable ligand binding model with the injection of a
low SA labelled ligand such as fiumazenil [48].
3.4 Identifiability
Structural identifiability refers to the theoretical process of ascertaining whether
a model is well defined when fitting to experimental data. Theoretical structural
identifiability analysis is the process of examining the model in the case of per-
fect data and determining whether model parameters can be obtained. Many
models have parameters which cannot be determined given perfect data [49] [50],
so it is very important to establish whether a model is robust before fitting to
k2
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Figure 3.3: Identifiability
any data. An experiment is declared uniquely (globally) identifiable if all the
parameter values are uniquely determined from noiseless input-output data. It is
locally identifiable if a finite discrete set of parameter values are determined and
unidentifiable if an infinite number of possible parameter sets exist.
The method of structural identifiability is directly applicable to compartmental
models, and has been used extensively to examine the viability of compartmental
systems [51] [52] [53] [54]. The methods available examine the properties of the
mapping of the parameters onto the system response. This mapping is defined by
the chosen model.
The scheme of structural identifiability is described in Figure (3.3). By postulating
a model, a map, M, is defined which maps from the parameter space,P, onto the
system response space,IR.
M:P—IR	 (3.5)
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If the mapping M is injective, i.e.
if P1 P2 implies M(pi ) M(p2 )	 ( 3.6)
then the model is globally (uniquely) identifiable. Essentially this means that
given two distinct system responses they are parameterised by different parameter
sets. A criterion for an ideal model would be that all the required parameters are
uniquely (globally) identifiable. However, in cases where the model is only locally
identifiable, it is possible to work out the finite number of parameter sets which
give rise to the system data. It may then be possible to discard some of these
parameter sets due to additional constraints that are known about the various
parameters or the system as a whole. Care can be taken to start fitting routines
in the neighbourhood of the required solution.
3.4.1 Introduction to Identifiability
Structural identifiability analysis is a technique which should be applied to model
structures to determine whether the unknown, independent, model parameters
can be deduced if perfect input-output data is available. The identifiability prob-
lem is fundamentally concerned with the uniqueness of solutions of a certain class
of mathematical models. Bellman and Aströrn in 1970 [55] were the first to put
identifiability analysis into a rigorous framework and they coined the term "struc-
tural identifiability". The expression "deterministic identifiability" is sometimes
used to avoid problems with the term structural when the identifiability properties
of the system are influenced by the type of input. When the model is deterministic
and the data are noise-free, the problem is generally a nonlinear algebraic one.
However, the solution to this problem is generally both nontrivial and nonunique.
With the addition of noise to the data the problem becomes extremely compli-
cated and is referred to as a problem of "numerical identifiability". One method
of analyzing numerical identifiability is to examine the standard deviation of each
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parameter estimate [56]. Another example of numerical identifiability is ensur-
ing that the number of measurements exceeds the number of parameters to be
estimated.
3.4.2 The Laplace Transform Approach
By employing the Laplace transform to differential equations generated by a par-
ticular model this enables the process of identifiability of the system parameters to
be undertaken. For (SISO) linear systems the identifiability analysis is performed
by examining the transfer function, TF(s), of the system. The system variables
are defined in the following manner,
Y(s) TF(s)U(s)	 (3.7)
where Y defines the observation and U defines the input.
For linear compartmental systems the transfer function is a quotient of polyno-
mials in s. Interrogation of the coefficients in the transfer function allows the
identifiability properties of the parameter vector to be established. Given perfect
data one would be able to measure the values of the coefficients in the measurable
transfer function, Y(s)/U(s), and so these values can be considered as measured
constants. The investigation of the identifiability of the system is concluded by
examining the' solution of a system of generally nonlinear equations. These equa-
tions are determined from the coefficients in the numerator and denominator of
the transfer function which are equal to measured arbitrary constants.
Establishing the system of nonlinear equations is straightforward, but the problem
with this method is that the solution is often difficult to determine when more
than a few equations exist, due to the nonlinearity. However the use of symbolic
manipulation packages [57], such as MATHEMATICA, often simplify this process.
The Laplace transform approach for identifiability analysis has been applied to
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many linear systems [58] [59] [60] [61] [62].
3.4.3 The Taylor Series Approach
This method involves expressing the observation, Y(t), as a Taylor series about
some known time point, say t = 0+ for an impulse response, with the successive
coefficients being constructed from the unknown model parameters [53] [51], i.e.
(t) = Y(o) + t(o) +	 (0k) +...	 (3.8)
The successive derivatives are measurable, given perfect data, and unique and
contain information about the unknown parameters which are to be identified.
Chapter 4 describes the Taylor series method in more depth and goes on to intro-
duce a novel method for the reparameterisation of unidentifiable systems.
The principal advantage of the Taylor series method is its applicability to nonlin-
ear and time varying systems as well as linear systems. It suffers from the same
problems as the Laplace transform method in that the algebraic equations con-
structed are often difficult to solve for all but the simplest of systems. Once again
the use of a symbolic manipulation package becomes invaluable. A drawback in
the method is that no upper bound exists on the number of coefficients that need
to be calculated for nonlinear models. For linear systems an upper bound can
be obtained by utilising the Cayley-Hamilton Theorem which declares that there
are, at most, 2n-1 independent equations required in this set [63]. It is important
to note that this is a necessary but not sufficient condition for identifiability.
3.4.4 The Similarity Transform Approach
The similarity transform, or exhaustive modelling, approach [52] [54] [64] proceeds
by generating all output indistinguishable models which are compatible with the
assumptions of the model. The method is most easily defined in terms of matrix
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notation. The system can described by
*(t,p)	 A(p)x(t,p) + B(p)u(t)	 (3.9)
with
x(0,p) = xo	 (3.10)
y(t,p) = C(p)x(t,p)	 (3.11)
with t E [0,T],x(t,p) E J,y(t,p) E m ,p E l C and u(t) E U[0,T]. A is
the system matrix (n x n), B is the input matrix (n x noinputs), and C is the
output matrix (m x n).
All equivalent models must have corresponding matrices A', B', C' related to A,
B, C by a similarity transform.
A' = TAT-'
B'=TB
	 (3.12)
C' = CT-'
A necessary condition for applicability of the similarity transform approach is
that the model is both structurally controllable and also structurally observable.
If these conditions are met, then the method is employed by applying (3.12) and
known constraints on A, B, C to determine the unknown elements of T [65].
The identifiability properties are then determined by the dimension of the set
of possible matrices, T. If T=I the system is uniquely (globally) identifiable, if
there is a finite set of possible matrices, T, the system is locally identifiable and
when the set has infinite dimension the system is unidentifiable. Examples of the
similarity transform approach as applied to linear systems are given by Chapman
and Godfrey [66]. The similarity transform approach may also be applied to
nonlinear models [52] [64].
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3.4.5 Other Identifiability Techniques
The Volterra series approach [67] extends the Laplace transform method to con-
sider nonlinear systems. Ljung and Glad have presented a differential groups
approach [68]. The method examines for global structural identifiability by con-
sidering whether the model can be rearranged as a linear regression. Both of these
methods are extremely difficult to apply for all but the simplest systems, due to
the complex algebraic equations generated.
3.4.6 Summary
This chapter has briefly reviewed some modelling approaches applicable to PET
and has presented various methods for performing identifiability analysis. The
choice of which method makes the identfiability analysis simplest is not straight-
forward and a certain amount of trial and error is normally required [54] [64]. In
the next chapter, novel work is presented which considers what can be done when
a system is unidentifiable. The system is reparameterised in terms of a reduced
parameter set, which guarantees the system to be locally identifiable.
3.4 Identifiability	 31
3.4.5 Other Identifiability Techniques
The Volterra series approach [67] extends the Laplace transform method to con-
sider nonlinear systems. Ljung and Glad have presented a differential groups
approach [68]. The method examines for global structural identifiability by con-
sidering whether the model can be rearranged as a linear regression. Both of these
methods are extremely difficult to apply for all but the simplest systems, due to
the complex algebraic equations generated.
3.4.6 Summary
This chapter has briefly reviewed some modelling approaches applicable to PET
and has presented various methods for performing identifiability analysis. The
choice of which method makes the identfiability analysis simplest is not straight-
forward and a certain amount of trial and error is normally required [54] [64]. In
the next chapter, novel work is presented which considers what can be done when
a system is unidentifiable. The system is reparameterised in terms of a reduced
parameter set, which guarantees the system to be locally identifiable.
Chapter 4
Unidentifiable Models and
Reparameterisation
4.1 Overview
This chapter considers a novel method of locally reparameterising unidentifiable
systems. This reparameterisation reduces a system to its minimal form (in the
sense of the number of parameters in the reparameterisation) and ensures that all
the parameters are (at least) locally identifiable. The chapter presents a theorem
which gives conditions for the existence of a reparameterisation. A theorem is
also presented which shows how a reparameterisation may be calculated. In the
second part of the chapter examples of four unidentifiable systems are given for
illustrative purposes. The examples consist of two standard PET compartmental
models (a reference region model and a nonlinear ligand binding model) and two
other examples (a linear system and a nonlinear batch reactor model). This
method of reparameterisation is applied to a metabolism model in Chapter 5.
4.2 Introduction
The determination of the structural identifiability of system parameters is an im-
portant procedure since it is a necessary prerequisite for experimental design. Over
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recent years a large amount of work has centred on the development of analyti-
cal methods and approaches for the determination of the identifiability of system
parameters both for linear and nonlinear models (see for example [51] [52] [53]
[54] [68] [64] [69] [70]). An important question is 'what can be done with uniden-
tifiable parameters and systems ?'. Aside from obvious model simplification or
redesign of the experiment considered, little has been conjectured theoretically
except for the ideas presented in [71] [72] [73] [74]. Milanese and Sorrentino [71]
consider a method for analysing unidentifiable linear models which involves clas-
sifying the parameters as identifiable or having some degree of freedom. This is
achieved by looking at the coefficients yielded by the transfer function. Rothen-
burg [72] considers how the rank of the system's Jacobian matrix can be utilised
in assessing the identifiability of the system parameters. Cobelli and Toffolo [73]
consider how parameter bounds can be derived for linear systems by using con-
straints implicit in a compartmental structure. Walter and Lecourtier [74] use the
exhaustive modelling approach to obtain the whole set of output indistinguishable
linear compartmental models.
In this chapter, a method is presented which offers criteria for the existence of a
locally identifiable reparameterised version of an unidentifiable system. A method
for determining the reparameterisation using identifiable parameter combinations
and a state space transformation is introduced. This reparameterised system is
essentially a reduction of the original system to its minimal locally identifiable
form (with respect to the parameterisation). The Taylor series approach [53] and
Pohjanpalo's Jacobian rank test [75] are employed which means that the approach
is applicable to both linear and nonlinear systems and also systems with specified
inputs.
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4.3 Background Theory
4.3.1 General System
Consider a system of the form
f(x,u,O,t,)
y(t) = g(x,O,t)	 (4.1)
x(0) = Xo(9)
where x e , y E u E U (an appropriate space of input functions: usually
piecewise continuous functions on an interval U[O, TJ which have infinitely many
derivatives with respect to t) and 9 E I C P where 1L. is the feasible parameter
region and 9 is a p-dimensional parameter vector. The functions f and g are
assumed to be analytic in each component.
4.3.2 Structural Identifiability
The identifiability of system (4.1) is examined at some parameter value 9 E
	
in
the experiments specified by (x0 , U[O, T]), where the initial conditions x 0 are well
defined once 0 is selected [64]. The notation 9 r' 0 denotes that the parameter
values 9, 0 e	 are indistinguishable in the experiments (x 0 , U[O, T]). System
(4.1) is defined to be globally identifiable at 0 E
	
if 0 U, 0 1, implies 0 = U,
and it is defined as locally identifiable if there exists an open neighbourhood ,,
of 9 in such that 0 i-..' 0 for 9 E fZ implies 9 = 0. These definitions can be
extended generically so that (4.1) is globally (locally) structurally identifiable if
it is globally (locally) identifiable at all 0 E 1, except (at most) the points of a
subset of zero measure in c. Furthermore (4.1) is unidentifiable if the system is
neither locally or globally identifiable.
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4.3.3 Taylor Series Approach
The Taylor series approach [53] examines for the structural identifiability of a
parameterised system assuming that y and its derivatives, evaluated at some t =
are available and perfect (noiseless), i.e.
(0)	 (1)	 (2)	 (n)
	
Yi (to)	 Yi (to)	 (t0)	 Yi (ta)
,...
	
(to)	 (to)	 yS, (to)	 (to)
These are essentially measurable constants (and in particular are independent of
0). Denote these coefficients by
(0)	 (1)	 (2)	 (n)
Yi	 Yi	 Yi	 Yi
:	 ,	 :	 ,	 ,...,	 :
(°)	 (1)	 ?I(2)Y,m	 Y7.	 .Jm
Then the Taylor series approach involves comparing
(0)	 (0)	 (1)	 (1) (0)	 (2)	 (2)	 (n)	 (n)y	 =g (0),y	 =g	 ,y	 =g (0),...,y	 =g2 (0),...
fori=1,...,m
in order to solve for 0. The number of solutions for 0 defines the identifiability
structure of the system.
4.3.4 Pohjanpalo's Rank Test
For some 00 E
	
consider the infinite Jacobian matrix of derivatives of the Taylor
series coefficients of y with respect to the parameter vector 0, i.e.
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0g(° ) (00 )	 •
aoi
50
5g(k)(OO)
'90i
ög(°) (00)
'90p
'90p
ôg(k) (o0)
(4.2)
Pohjanpalo's result [75] states that the parameters 9 = (0k, °2 ..., 0) are locally
identifiable if and only if G (00) has rank p. This follows from the rank theorems
provided by Rothenburg [72].
In order to extend the result of Pohjanpalo to consider unidentifiable systems the
Implicit function theorem, and a corollary of the Rank theorem are required [76].
Theorem 1 (Implicit Function Theorem [76]). Let A c	 x m be an open
set and let F : A _ m be a function of class cr (that is F has r continuous
derivatives where r is a positive integer). Suppose (xo,yo) A and F(xo,yo) = 0.
Form the determinant of the submatrix given by
8Ym
(4.3)
...
'9y1
	
8Ym
evaluated at (x0 , y0), where F = (Fi ,.. . ,Fm ). Suppose that L	 0. Then there is
an open neighbourhood U C
	
of x0 and a neighbourhood V of Yo in m and a
unique function f : U -* V such that
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F(x,f(x))	 0	 (4.4)
for all x E U. Furthermore, f is of class cT.
A corollary of the Rank theorem is also required.
Corollary 1 [76] Let G: A C	 (where A is open in ) be a function
of class CT such that DG(0) has rank q for all 0 in a neighbourhood of 00 E A.
Then there is an open set U1 C	 an open set U2 C J' with 00 E U2 , an open
set V1 around G(0°), an open set V2 C	 and functions h U1 -p U2 and
f: V1 -^ V2 of class CT with inverses of class CT such that f o Go h(01 ,. . . , O) =
(oi,...,Oq,O,. ,O).
4.4 Existence of a Reparameterisation
Theorem 2 Given a function Y(01 ,. . . , 0, t) whose Taylor series expansion gives
rise to the coefficients gi(0),. . . ,g,(0) where gi : A C	 -* for i	 1,... ,p.
Define C = (gi,. . . ,g). Suppose that the Jacobian matrix DG(0) with respect to
0 has rank q(< p) for all 0 in a neighbourhood of 0° E A then the function Y may
be locally reparameterised in terms of a set of q of the Taylor series coefficients,
ci =gji ,.., q q gjq}	 (45)
i.e.
(4.6)
Furthermore the reparameterised system is locally identifiable.
Proof : If DC (0°) has rank q for some q < p then by Corollary 1 there exists
an open set U1 C	 an open set U2 C R' with 00 E U2 , an open set V1 around
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an open set V2
 C P, and functions Ii: U1 -* U2 and f : V1 - V2 of
class C' with inverses of class Cr such that
foGoh(Oi,...,Op)(Oi,...,Oq,O,...,O).	 (4.7)
Let M :	 -* p-q be the last p - q components of f, hence,
Mi (gi ,.. . , gp )	 = 0
(4.8)
Mp_q (gi ,.. .,g,) = 0
Since f is invertible, the Jacobian matrix DM with respect to gi,.. . ,gp} must
have rank equal to p - q where
oM1 (O°)	 8M1(O°)
agp
DM=	 :
	 (4.9)
t9Mp_q(90 )	 ôMp_q(00)
'9gi	 9g
Now by the definition of the rank being the number of linearly independent rows
or columns of a matrix there exists a partitioning of C =	 . , gp} into two sets
A and B where A =
	 . . ,gjp_q} c G, B = 19ip_q+i . . ,g} C C, AflB	 0}
and A U B = C such that the determinant, , is
0M1 (o°)
	
aM1(o°)
ôgj1	 '9gip_q
ôMp_q(00 ) . . • ôMp_q(00)
0.	 (4.10)
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Now by invoking the implicit function theorem it follows that we can locally solve
Mi(gi,...,g)	 = 0
(4.11)
MN_q(gl ,. . . ,gp) = 0
for
gj1	 =	 L j (gip_q1 ,. . . , g)
(4.12)
gipq = Lp_q (gip_qi ,. . . , gd,,)
where L : -p p-q Now
	
G(01,. .., O ) = (gi,.. .,gp)	 (4.13)
and from equation (4.12) this can be represented as
G(0 1 ,. . . , O,)	 =	 (4.14)
where q'i
	 gip_q1 ,. . . ,	 =
Finally by application of Pohjanpalo's rank test the parameters i,. . . ,
	
are
(at least) locally identifiable.
0
Remark : The reparameterisation deriving from the implicit function theorem is
only guaranteed in a neighbourhood of 00. The theory also applies to the Nth
order Taylor expansion of the function Y.
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As an extension to Theorem 2 let us consider the conditions on for a reparame-
terisation to exist, i.e what are the "new" parameters (h,. . . , q) with which the
system can be reparameterised.
Theorem 3 Given
C(01,. . . ,O) =
	 . . ,q)	 (4.15)
as in Theorem 2 where q <p such that rank (DG(O°)) q and let the kernel, NG,
of(DG(O°)) be given by,
NG = I 8 E RYIDG(O°).6 = 0}. 	 (4.16)
Now given
(4.17)
Suppose that
<D(9°),N>	 0	 (4.18)
where <,> is the Euclidean inner product on 	 and that
rank(D(O°)) = q
	
(4.19)
then there exists a O such that
G(91,...,O) = Ô(ci,...,qq)	 (4.20)
Furthermore if (.18) and (.19) are not met then no such O exists. (i.e. the
function ,G , can be reparameterised in terms of the parameter set (& . , q) if
and only if conditions ($.18) and (4.19) are true).
Proof: If
G(01,. . .,O) =
	
(4.21)
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then
DG(0) = DO((0)).DI(0) 	 (4.22)
Given
DG(0).NG =
D(t9).NG = 0,
rank(D(0)) = q,
(4.23)
let MG be the q dimensional complement of NG such that MG fl NG 4 0} and
MG e NG = Then
DG(0).NG = DG((0)).D(0).NG	 (4.24)
which implies that
0 = DO((0)).0	 (4.25)
and this is satisfied for all O. But O must also satisfy
DG(0).MG
 = DO((0)).D(0).MG.	 (4.26)
Now D(0).MG is a qxq matrix with rank q and therefore has an inverse such
that
DG(0).MG(D'(0).MG)1 DO(''(0)).	 (4.27)
Hence there exists a function	 such that (4.22) is satisfied. Furthermore it is
trivial to show that if NG N (where	 = 40 E	 lD(0°).0 = 0}) then (4.22)
is false and no G exists. Choose D(0).N = 0 which implies that DG(0).N	 0
and hence
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DG(0).N = DO(4(0)).D4(0).N	 (4.28)
which implies
DG(0).N = 0
	
(4.29)
and the desired result is achieved by contradiction.
4.4.1 Reparameterisation
This section briefly describes the methodology for reparameterising an unidentifi-
able system. Firstly the nullspace,NG , of the Jacobian matrix C is calculated and
it is spanned by
NG = [a1,... ,ap_q]
	
(4.30)
where the vectors a, for i = 1,.. . , p - q are p dimensional. The locally identifiable
parameters for the reparameterisation may be calculated from the conditions given
in Theorem 3, i.e. the new parameters = ( q i,. . . , q) must satisfy,
< [f- ' . . . , fLF, [ai,.. . ,ap_q] > = 0.	 (4.31)
for i = 1,. . . , q. This produces a partial differential equation whose solution yields
the required functions qj. For the case p - q = 1 the partial differential equation
is given by
ôqj fli 1 + ... +	 = 0	 (4.32)9O
Once q solutions have been found such that rank (D) =q then by Theorem 3
there exists a reparameterisation of the system involving just these q parameters.
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The final stage involves finding a state space transformation of the original dif-
ferential equations such that the system may be reparameterised in terms of the
new parameter set . This step is nontrivial and the choice of simple functions
for gives the best chance of finding a simple state space transformation.
4.5 Method of Reparameterisation
The idea behind reparameterising the system involves finding locally identifiable
parameter groupings and then a state space transformation such that the trans-
formed equations only involve these identifiable parameter groupings. Firstly, a
simple way of obtaining identifiable parameter combinations from the nullspace of
the Jacobian matrix is described. To illustrate the situation consider the problem
geometrically for a three parameter system, see Figure (4.1). Henceforth examples
will only be considered for systems where the Jacobian matrix is rank deficient by
1,(i.e q = p - 1) although the ideas presented here apply for higher dimensions of
rank deficiency. If the system under consideration is locally identifiable (i.e. full
rank Jacobian, q = p) then a set of experimental data will map back to a distinct
point or finite number of points in parameter space. However in the case where
the Jacobian is rank deficient by 1, (q = p - 1) the experimental data will map
back to a curve in parameter space.
Let the nhllspace of the corresponding Jacobian matrix C be spanned by those
vectors	 which satisfy,
Gn=	 (4.33)
For q p - 1 the nulispace of the Jacobian matrix is spanned by a vector which is
tangent to the solution curve at all points in parameter space. Hence the nulispace
gives the local direction in which a solution for the parameters may be perturbed
such that the observation y is unaffected. If the nullspace has any zero entries the
corresponding parameter is identifiable because the nullspace is orthogonal to this
02 02
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Identifiable System: G has Full Rank	 Unidentifiable System: G is Rank Deficient by 1
03	 93
01
	 01
Figure 4.1: Parameter space for a three parameter system
parameter axis. However for a non-zero entry this implies that it is possible to
perturb this and other parameters in a way such that the observation, y, remains
unchanged.
Consider a family of functions, (0k , 02 , 03) where qj : -p (i=1,2), such
that the image of qj is a locally identifiable combination of the parameters. Any
function 4j will have a directional derivative in the direction of the nulispace
equal to zero, see Figure (4.2), i.e. moving in parameter space in such a way
that the observation y remains unchanged, the function 1i has a constant value.
To calculate the functions qj whose directional derivative in the direction of the
nulispace vector is zero requires that,
<Dq,> =0	 (4.34)
where Dq(0) is the gradient of the function q5.
For our three dimensional example the partial differential equation which provides
solutions for q is
02
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Unidentifiable System: G is Rank Deficient by 1
03
1
Figure 4.2: Parameter space for a three parameter system
Dq	
= 0.	 (4.35)
—ni+----n2+	 ri3D0	 302	 303
Any new parameter defined by the image of çj which solves equation (4.35) is
locally identifiable, as the directional derivative in the direction of the nullspace is
zero and hence this parameter must be fixed for each distinct observation. There
is no unique solution for qj to equation (4.35).
To reparameterise the system it is necessary to find a set of q(= 2 in this case)
identifiable parameter combinations which span the manifold in parameter space
describing all possible system responses. Firstly, 2 locally identifiable parame-
ter groupings q and q are deduced from the partial differential equation in qj
(equation (4.35)), such that these parameters are independent (see Theorem 3).
Normally the boundary values in (4.35) are chosen to be zero and this is the case
in the following illustrative examples. The final step in the reparameterisation
involves finding a state space transformation which reconstructs the original set
of equations such that they only involve these 2 identifiable parameter group-
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ings. The new parameter groupings and the state space transformation constitute
the reparameterisation of the system. By determining the identifiable parameter
groupings first it facilitates the discovery of an appropriate state space transfor-
mation by inspection.
4.5.1 Summary of Reparameterisation Process
• Calculate the Taylor series
The Taylor series of the observation is evaluated at some t = to
from the system equations and initial conditions.
• Calculate the Jacobian matrix and its associated rank
Calculate the partial derivatives of the Taylor series coefficients
(see Discussion).
• Determine the identifiable parameter combinations
Calculate the nullspace of the Jacobian matrix G by employing
row operations. Utilise the nullspace to calculate locally identi-
fiable parameter combinations using Theorem (3).
• Determine the state space transformation
By inspection of the system equations construct a state space
transformation which converts the system into a form which is
parameterised by just q locally identifiable parameter combina-
tions which span the viable parameter space. The state space
transformation must preserve the input-output map of the sys-
tem.
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4.6 Examples
To illustrate the methodology and results presented for minimally locally identifi-
able forms of parameterised systems four examples are considered. Example 1 is a
standard 2-dimensional linear system in which observation is of one compartment
only. Examples 2 and 3 are standard PET models for ligand binding. The repa-
rameterisation of example 3 puts into a more rigorous context the parametrisation
that has previously been applied empirically [77]. The 4th example does not re-
late directly to PET studies but is included as an example to demonstrate the
methods full power with a non-trivial reparameterisation of a nonlinear system.
For the purpose of the examples the parameters are assumed to be dimensionless,
the dimensions having no effect on the reparameterisation process.
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4.6.1 Example 1 : Linear System
Consider a two dimensional linear system defined by,
dxi(t)
= 01 x 1 (t) + 02 x 2 (t) + u (t)dt
dx2(t)
= 03x 1 (t) + 04 x 2 (t)dl
y(t)=x2(t)
x 1 (0) = 0
x 2 (0) = 0
(4.36)
The experiment considered is for a unit impulsive input, u (t) = S (t), with oh-
servation of x 2 only. Thus the system can be considered to have zero input and
non-zero initial conditions, i.e.
u(t) = 0
x 1 (o+) = 1
x 2 (o+) = 0
(4.37)
For this system it is a straightforward procedure to generate the Taylor Series co-
efficients of the observation function y of which the first three non-zero coefficients
are given by :-
(l) (o+)	 03
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(2)(of) =03(01+04)
(3)(o+ ) = 03 (o + 02 03 + 004 + o)
(4.38)
By taking partial derivatives of the Taylor series coefficients of y with respect to
the parameter vector 0 (0k , 02, 93 ,04) the following Jacobian matrix is obtained,
0	 0
03	 0
03 (201
 + 04) 23
1
0 + 04
O + 200 + 004
 + 0
0
93	 (4.39)
03 (0+ 204)
By a process of row reduction the matrix can be reduced to
100	 1
G' (o°)	 0 1 0 - +
	
(4.40)
001	 0
It follows that the matrix,G (00), has rank 3, since using Vajda's result [63] con-
cerning structural identifiability of linear systems, we know that there are at most
3 (2n-1) independent equations that can be obtained from the Taylor coefficients
(where n is the dimension of the state space of the system). Hence it is implicit
that no more terms need to be calculated as the matrix will only ever have rank
less than or equal to 3. Using Theorem 2 there is 1 (p - q) redundant param-
eter and there exists a reparameterisation of the system in terms of just three
parameters which is locally identifiable.
Reparameterisation of the System
For the Jacobian matrix G (00) the nullspace is spanned by the vector,
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[_i, 01-04 o, i]	 (4.41)
To solve for functions q whose images are identifiable combinations of the param-
eters consider,
1aq	 öq	 oq	aql I	 0j-04
L'	 '	 '	 ' L'	 03	
o, i] > = 0	 (4.42)
Hence the following partial differential equation in q is obtained,
aq	 o1 —o4 aq	 o
+ 03	 +	
= 0	 (4.43)
Possible solutions for are,
0104
ql(Ol, O2, O3, O4) = 02 -
2(01,02, 03 , 04 ) =
3 (01 , 02 , 03 , 04 ) = 0 + 04
(4.44)
where = 1, 2, 3} and rank DJ? = 3.
The original system (4.36) may now be rearranged to include just these three
parameter groupings as and hence may be reparameterised in terms of them. Let
= x(t) - -x2(t)
Substituting into the original pair of equations yields,
dxi ( t)*
	0 dx2(t)	 0i(xi(t)* + x2 (i)) + 02 x2 (t) + u (t)+-03 dt
dx2(t)
= 03 (xj (t) + x2 (t)) + 04x2(t)dt
(4.45)
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Subtracting - times the second equation from the first and simplifying yields,
dxi(t)*	 0104
dt = (02 - —)x2(t)+u(t)03
dx 2 (t) -
cit - 03x1(t)* + (0 + 04)x2(t)
(4.46)
Hence a reparameterised version of system (4.36) which is a locally identifiable
system is given by,
dx1 (t)*
= q i x 2 (t) + U (t)
dt
dx2(t)
dt - q2xi(t)* + cb3x2(t)
y (t) = X2 (t)
Xi (o+)* 
= 1
X2 (o+ ) = 0
(4.47)
where q = 02 -	 -, q 2 03 , and	 = 0 + 04 are locally identifiable. Note that
the reparameterisation is not unique and that the parameterisation of the system
has been reduced from p(=4) to q(=3) parameters.
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4.6.2 Example 2 : Nonlinear Saturable Ligand Binding
Model
A typical example of a ligand whose kinetics are accurately described by the
model shown in Figure (4.3) is flumazenil which binds reversibly tO benzodiazepine
receptors [78]. Flumazenil is an ideal ligand because it has a high blood brain
barrier permeability and a high specific to non-specific ratio [79].
A model for the binding kinetics of flumazenil has been described by Delforge
[56] and Price [48] and derives from the pioneering work of Mintun [80]. The
model is based on Mintun's receptor binding model which contains free ligand,
nonspecifically bound ligand and specifically bound ligand. In this model, the free
and non-specifically bound ligand are assumed to be in rapid equilibrium allowing
the model's complexity to be reduced by considering the free and nonspecifically
bound pools as one. The model is described by the compartmental form given in
Figure (4.3), and the following nonlinear system equations can be derived:-
P1asma,
IK
CAEJflk2
Tissue
I-------------------------------1
Li	 ik3JflCf[Cb
(B A)
max SA
Figure 4.3: Ligand binding compartmental model
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dCf(t) - K1Ca(t) (k
	
konBmax \	 kQCf(t)Cb(t)
dt -	 - 2 + --- ) 
C1 (t) + k0ffCb (t) +
	 V.SA
dCb (1)	 konBmaxCf (i) -	
- konCf(t)Cb(t)
dt -
	 Vr	 /coffCb(t)	 VrSA
y(t) = Cf (t) + Cb(t)
(4.48)
where
K	 is flow x extraction
k2	 is the efflux rate constant
Bma is the maximum concentration of available binding sites
is the volume of reaction
k0	 is the apparent 2nd order association rate constant
k0ff	 is the dissociation rate constant
SA	 is the specific activity of the compound
A nonlinear term is an intrinsic part of the model because the rate at which the
free ligand binds to the receptors depends on the concentration of available binding
sites. The rate at which the free ligand binds is defined by Ic3 = kpBp where the
concentration of available binding sites,B a , is determined by the nonlinear term
Ba	 Bn,a - . j-. It should be noted that the constant V. is composed of two
factors; i) the volume within which the free ligand exists, and ii) the fraction of
ligand which is free to bind.
The rate constants k0 and k0ff in the model derive from theory first applied to
pharmacological systems by Clark [81] (cited in [82]) in which he laid down the
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foundations for receptor occupancy. The equations are defined as,
[L]+[R]	 [LR]	 (4.49)koff
where
[L}	 is the concentration of free ligand
[R]	 is the concentration of receptors
[LR] is the concentration of bound ligand
k0	 is the 2nd order association rate constant
k0ff is the dissociation rate constant
By introducing a dose of high specific activity to the system the model can be
approximated by a linear system where k3 = konBrnar . This results from the fact
that the large value of specific activity renders the nonlinear term in the equation
negligible. However when a low specific activity dose of the compound is admin-
istered the system is nonlinear. The nonlinearity derives from the large amount
of cold compound available to bind to the receptors. The more available cold
compound reduces the number of available binding sites. Delforge has shown that
only five parameters are identifiable from this model because lc0 and Vr always
occur together in the system equations [83]. The reparameterisation process is
applied to this model showing how a simple reparameterisation is obtained.
The specific activity of the compound is known prior to administration and this
measured constant is removed from the following calculations without loss of gen-
erality by assuming that SA=1. The experiment is considered for a unit impulsive
input, Ca(t) = 8(t), with observation of the sum of C1 + Cb . Hence the system
can be considered as having zero input and non-zero initial conditions, i.e.
C1 (0) = K1
Cb(0) = 0
(4.50)
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It is then possible to calculate the Taylor Series coefficients of the observation
function y(t). The first five Taylor series coefficients are :-
y(0) (o+) = K1
y(1 )(o+) =—(K1k2)
(2) (o+)	 K1k (k2 V7. + kBma)
Vr
(3) (o+)	 I( k2
= - TT 
2 (k22V7.2 + Ki kon 2 Bmax + 2k2 k0
 VrBma + kon2Bmax2
r
+k0 VrBmaxkoø)
(4) (o+)	
I(1k2
- V3 
(k23Vr3+Ki2kon3Bmax +4Ki k2 kon 2 VrBmav +3k22konVr2Bmaa+
I.
41(1 k 3B
 2 +3k2 1CO 2 VB 2 k
 3B
 3 +21(J kon 2 Vr Bma ICoffr moz U on mazon maz
+2kkon. V7. 2 Bmakoff + 2kon 2 Vr Bmaa?koff + k0 Vr 2 Bmaz koff 2 )	 (4.51)
The Jacobian matrix is obtained by taking partial derivatives of the Taylor series
coefficients with respect to the parameter vector 0 (Ki , k2 , k0 , V., Bmax, k0ff).
The Jacobian matrix, 0(00), is given in Appendix A.1. By a process of row
reduction, within MATHEMATICA, the Jacobian matrix can be reduced to,
100
010
0 0 1
000
000
0	 00
0	 00
—00
o	 10
0	 01
(4.52)
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Therefore the rank of the Jacobian matrix, C (0°), is at least 5. Using Theorem
2 there is 1 (p - q) redundant parameter and there exists a reparameterisation of
the system in terms of just five parameters which is locally identifiable.
Reparameterisation of the System
To consider what reparameterisation of the system will render the model identifi-
able it is necessary to calculate the nulispace of the Jacobian matrix, G (0°), given
by 4.52. The nulispace of G (0°) is spanned by the vector,
n= [oO1,o,O]	 (4.53)
Applying Theorem 3 the locally identifiable parameter groupings are determined
from,
1 dq	 dçb dçb dçb
	
dq	 dq5l
L''''dBmax'dkoijj	 > = 0	 (4.54)
This yields a partial differential equation in qf(0) such that all solutions 4(0)
satisfying this equation are locally identifiable. The partial differential equation
in this case is given by,
L dc/	
-	 (4.55)
VrdkomdVr
Solutions to (4.55) are found by inspection. The following simple locally identifi-
able parameter combinations are obtained,
1 (K1 , k2 , k0 , Vr, Bmav, k011 ) = i(i
cj 2 (Ki ,k2 ,kon ,Vr ,Bmac,koff ) = k2
3(Ki,k2,kon,Vr,Bmax,koff)
q 4 (Kj ,1c2 ,k0 ,Vr,Bmax,koff) Bmaz
4.6 Examples	 57
c/5(Kl,k2,kon,Vr,Bma,koff) = koff
(4.56)
where =	 2, 3, 4, q} and rank D1' = 5.
This leads us to a simple reparameterisation of the model in which the parameter
combination k0/V is introduced as a new parameter. This illustrates the method
of reparameterising an unidentifiable system even though the reparameterisation
for this example is simple and could have been deduced fairly easily from close
inspection of the original equations. Hence the locally reparameterised version of
system (4.48) which is locally identifiable is given by,
dCf (t)
	
	 ____
= K1 Ca(t) - (k2
 + k:nBmax) Cf (t) + koff Cb (t) +dt
dCb - k* B Cf(t) - k0ffCb(t) -
-	
ma
y(t) = Cf (t) + Cb(t)
(4.57)
where k
Note that the reparameterisation is not unique and that the parameterisation
of the system has been reduced from p (= 6) to q (= 5) parameters. Sometimes
a vascular component is included in the model to take into account a blood vol-
ume component in the region of interest [84]. The inclusion of this vascular term
in the observation function y(t) yields the same result as before with the blood
volume term being identifiable and hence no further reparameterisation is neces-
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sary. Often this component is fixed using a priori knowledge arid hence reduces
the number of kinetic parameters to be estimated. Further analysis of this model
with respect to numerical identifiability and different protocols is described by
Delforge [84].
The parameters of interest generally are Bmaz, and Kd the maximum concentra-
tion of binding sites and the equilibrium dissociation constant (or half saturation
concentration, Kd = ----), respectively. B,-,.ax is locally identifiable from a single
experiment, given that the specific activity is suitably small and the experiment
can be considered nonlinear. Hence to identify the parameter Kd it is necessary
to either know Vr a priori or to perform an in vitro experiment to ascertain its
value [481 [85] [83].
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4.6.3 Example 3: Reference Region Model
Tissue
iIiil
CfLCb
CA
Figure 4.4: Reference region compartmental model
A reference region model described by Blomqvist [86] and Cunningham [77] pro-
vides a method of avoiding arterial blood sampling. The method relies on the
fact that there exists an area in which little or no specific binding is present. A
region of interest is defined on this reference region such that the kinetics of the
free ligand can be obtained. The model is illustrated by the compartmental model
given in Figure (4.4).
The compartmental model is described by the following set of ordinary linear dif-
ferential equations,
dCref (t)
dt	 = K5 Ca (t) - k6Crej(t)
dCf(t)
= K1 Ca (t) - (k2 + k3) Cf (t) + k4Cb(t)dt
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dCb(t)
dt = 
k3 C1 (t) - k4Cb(t)
y(t) = Cf (t) + Cb(t)
(4.58)
where
Crei (t) is the concentration of label in the reference region
Cf (t)	 is the concentration of label in the combined free and nonspecifically
bound pools
Cb(t)	 is the concentration of label in the specifically bound pooi
Ca(t)	 is the concentration of parent ligand label in plasma
K1	 is flow x extraction
is the efflux rate constant
is the product of the association rate constant and the maximum
specific binding capacity (tracer conditions only)
Ic4 	 is the dissociation rate constant
is flow x extraction in the reference region
k6
	is the efflux rate constant for the reference region
Transformation of the system equations (4.58) allows us to remove the presence
of the term Ca (t). Rearrangement of the first equation gives,
dCref(t) 
+ k6Cref(t)
Ca(t)
K5	
(4.59)
Substituting this equation into the second of (4.58) eliminates Ca(t) yielding,
dCf (t)	 ii9ref (t) K1k6 Cref (t) - (k2 + Ic3 ) Cf (t) + k4Cb(t)
dt	 K5 dt
dC&(t)	 ksCf (t) - k4Cb(t)
dt
Cf(t) + Cb(t)
(4.60)
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Cref (t) may now be treated as the input for this system. The system is examined
for a constant input,
0 t<O
Cre1(t)1 1 t>O
dCref (t) -
dt	
- 6(t).
(4.61)
This system can be considered as having zero input and non-zero initial conditions,
i.e.
dCf(t) - K1k6
_______ _____ - (k2 + k3 ) Cf (t) + lc4Cb(t)dt - K5
dCb (t) -
k3 Cf (t) - k4Cb(t)dt -
y(t) = Cf
 (t) + Cb(t)
K1
Cf (0) =
Cb(0) = 0
(4.62)
The Taylor series of the observation function y(t) expanded about t = 0 can now
be calculated. The first five Taylor series coefficients are :-
(°) (o
	 =
" I K5
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(l) (o+) = K1 (k6 - k2)
K5
(2) (o+) = K1 k2 (k2 + k3 - k6)
K5
(3)
 (o+) 	
K1k2 ( k22 + 2k2 k3 + k3 2 + k3 k4 - k2 k6 - 1c31c6)
-	 K5
(4) (o+) 
K1 k2 (14 + 314k3 + 3k2 14
 + 14 + 2k2 k3 k4 + 214k4 + k3 k - 14k6
K5
—2k2 k3 k6 - 14k6 - k3k4k6)
K5
(4.63)
The Jacobian matrix G (00), consisting of the partial derivatives of the Taylor
series coefficients with respect to the parameter vector 0 (K1 , k2 , k3 , k4 , 1(5 , k6),
can then be obtained. This process was performed using MATHEMATICA and
the coefficients are given in Appendix A.2. A process of row reduction of the
Jacobian matrix yields,
10
01
G(00) =
 0 0
00
00
0 0 
-f 0
00	 0	 0
10	 0	 0
01	 0	 0
00	 0	 1
(4.64)
It follows that the matrix,G (0°), has rank 5, since using Vajda's result [63] con-
cerning structural identifiability of linear systems, we know that there are at most
5 (2n-1) independent equations that can be obtained from the Taylor coefficients
(where n=3 is the dimension of the state space of the system). Using Theorem 2
there is 1 (p - q) redundant parameter and there exists a reparameterisation of
the system in terms of just five parameters which is locally identifiable.
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Reparameterisation of the System
Calculation of the nulispace of G (00) yields,
1
= [--,O,O,O,1,O]	 (4.65)
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By application of Theorem 3 the locally identifiable parameter groupings can be
derived by solving for in,
I dçb dq dçb dq dq dq1 {K1
Lk ,0,0,0,1,0] > 
= 0	 (4.66)
K1 dçb	
-o	 467K5 dK1 + dK5_	(. )
Solution of the differential equation yields the following simple locally identifiable
parameter combinations,
- K1
q i (K1 , k2 , k3 , k4 , K5 , k6)
q 2 (Ki ,k2 ,k3 ,k4 ,K5 ,k6 ) = k2
3 (K1 , k2 , k3 , k4 , K, k6 ) =
4 (K1 , k2 , k3 , k4 , K5 , k6) = k4
qs(K1 ,k2 ,k3 ,k4 ,K5 ,k6) = k6
(4.68)
where = 1, 2, 3, Q4, qs} and rank D = 5.
This leads us to a simple reparameterisation of the model in which the parameter
combination Rinflux = '- is readily introduced as a new parameter. Hence the
reparameterised system is defined by,
4.6 Examples	 64
dCf(t) - RflflXt)
di -	 dt	 + Rinfluxk6Cref(t) (k 2 + k3 ) C1 (i) + k4C&(t)
dCb(i)
di = k
3 Cf (t) - k4Cb(t)
y(t)	 Cf (t) + Cb(i)
(4.69)
Note that the reparameterisation is not unique and that the parameterisation of
the system has been reduced from p (= 6) to q (= 5) parameters.
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4.6.4 Example 4: Batch Reactor Model
A model of microbial growth in a batch reactor was introduced by Holmberg [87]
and further analysed by Chappell and Godfrey [501. The batch reactor model is
defined by the equations,
dx i (t)	 01x1(t)x2(i)
______ ___________ - 03 x 1 (i) + 04u 1 (I)
di - 02+x2(t)
dx 2 (t)	 - 01x1(t)x2(t)
+06u2(i)dt	 05(02+x2(t))
y(t)=xi(t)
x 1 (0) = 0
x 2 (0) = 0
(4.70)
where
x1 is the concentration of micro-organisms
x2 is the concentration of growth limiting substrate
is the maximum velocity of the reaction
02 is the Michaelis-Menten constant
05 is the yield coefficient
03 is the decay rate coefficient
04 is the initial concentration of micro-organisms
06 is the initial concentration of substrate.
The experiment considered is for impulsive inputs to both compartments, u1 (I) =
S (I) and u2 (i) = S (I), with observation of x 1 . Thus the system can be considered
to have zero input to both compartments and non-zero initial conditions, i.e.
ui (i) = 0
u2 (i) = 0
xi (0) = 04
x 2 (0) = 06
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The first five Taylor coefficients of the observation are obtained (within MATHE-
MATICA).
(o) (of) = 04
(l) (of ) = - (03 04 ) + 01040602 + 96
01 2 04 2 06 2 	 01204206	 91204962	 201030406y(2) (of) = 93294 
+ 05(02 + 06) - 05(02 + 96)2 
+ (
02
 + 06 )2 - 92 +96
y(3) (o) = - (03394) - 01 302 04306 2 	 2010406	 0130204206392(9 
+ 06) + 052(02 + 06) + 95(02 + 06) 
+
3 3a201 304 2 964	 01020406	 20 04 V6	 01302042062
05(02 + 06) 
+ 92(9 + 06) - 02(9 + 96) - 05(02 + 06) -
01 2 029304 2 06 2 	 01 3 04 2 063	 01203042063	 012020394206
05(02 + 96) 
+ 
05(02 + 96) - 05(02 + 96) 
+ 
05(02 + 96) -
301 3 94 2 06 2 	201203942062	 010406	 30120304206
05(02 + 06) - 05(02 + 06) + (02 + 06) + 05(02 + 06) -
301 2 030406 2 	3910320406
(02+06)2 + 02+06
15010406	 491030406	 _1101293294206 + 60120320405062y(4) (of) = 03 04 + 
05(02 + 06) - 02 +06 +
	
95(02 + 06)2	 +
—701 03 04 06 + 2201 3 03 04 2 05 06 2 + 1101 2 03 2 04 2 05 06 2 - 40139304052063
02(0 + 06)
—250 1 04 06 + 2501040506 +
+
O5(02 + 06)
2 2n 41101 4 04 4 06 2
 - 369 4 33 - 2191 93 04 05 06 + 11004 5 6
+
05(02 + 96)
- (o1 04 O6) + 1191 4 04 3 05 06 2 + 280139394305962
_1101 4 04 2 05 2 06 3 _22030029203 + 9149596
95(02 + 06)
Now for some 00 E
	
consider the Jacobian matrix of derivatives of the Taylor
series coefficients of y with respect to the parameter vector 0 =(0, 02, 03 , 04 , 05 , 06).
The coefficients of the Jacobian matrix are obtained using MATHEMATICA as
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the expressions involved are very large, the coefficients are listed in Appendix A.3.
Using MATHEMATICA it can be shown by a process of row reduction that the
matrix reduces to,
	
10000	 0
o i 0 0 0 -
	
G' (00) = 0 0 1 0 0
	
06	 (4.71)
	
00010	 0
	
00001	 -66
Hence Rank C (0°) = 5.
In [50] Chappell and Godfrey have shown that this model is unidentifiable and
hence the rank of the infinite Jacobian matrix must be less than 6. Using this
result and the previous calculations the infinite Jacobian must have rank 5 almost
always which implies that q = 5. Using Theorem 2 there is 1 (p - q) redundant
parameters and there exists a reparameterisation of the system in terms of just 5
parameters which is locally identifiable.
Reparameterisation of the System
For the Jacobian matrix G (00) the nullspace is spanned by the vector,
= [o	 , 0, 0, -, 1]	 (4.72)
To solve for functions q1 whose images are identifiable combinations of the param-
eters consider,
[0,	 : 0
	
05	 1
<[-,	 -,	 -,	 -,	 -,	 -j ,	-	
, 0, --, lj>=o (4.73)
Hence the following partial differential equation in q is obtained,
o6aO2o6a+a960	 (4.74)
2z
96
03
0405
0506
(4.75)
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Some possible solutions for are,
q i( Oi, 02 , 03 , 04 , 05 , 06)
2(01, 02, 03 , 04 , 05 , 06)
53( O1, 02, 03 , 04 , 05 , 06)
(0k , 02, 03 04 , 05 , 06)
5 (01 , 02, 03 , 04 , 05 , 06)
where = 1, 2, 3, 4, q s} and rank D't = 5.
The original system (4.70) may now be rearranged to include just these five pa-
rameter groupings and hence may be reparameterised in terms of them. Let
=
Substituting into the original pair of equations yields,
dx i (t) - O106x1(t)x2(t)* - 
03 x 1 (t) + 046 (t)
dt - 02+06x2(t)*
dx 2 (t)* -
	 0106x1(t)x2(t)* + 
066(t)06 dt
	
- 05(02 + 06x2(t)*)
(4.76)
or after rearrangement,
dx i (t) = Oixi(t)x2(t)* - 0
3x 1 (t) + 04 6 (t)
dt
06
dx 2 (t)* - - Oixi(t)x2(t)*
dt	
- 02 05
 + 0506x2(t)*
(4.77)
This system then simplifies to,
dxi (t) = 0iai(t)x2(t)* - 0
3x 1 (t) + 04 8 (t)
dt	 Z+x2(t)*
06
dx 2 (t)* - 
_______________
dt	 0s06(+x2(t)*) +6(t)
(4.78)
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giving the following locally identifiable system,
dxi(t) - ___________ -
4)3 x 1 (t) + 4)46 (t)
dt - 4)2 +X2(t)*
dx2 (t)*	 4)ixi(t)x2(t)* 
+6(t)
dt -
y(t)=xi(t)
xi (0) - 0
X2 (0)* = 0
(4.79)
where 4) = O, 4)2	 P-, 4) = 03 , 4)4	 and q = 0506 are locally identifiable.
Note that the reparameterisation is not unique and that the parameterisation of
the system has been reduced from p (= 6) to q (= 5) parameters.
4.7 Discussion
A method has been provided for reparameterising unidentifiable systems. The-
orem 2 presented here states that the rank of the appropriate Jacobian matrix
determines the number of locally identifiable parameters. Theorem 3 gives the
necessary and sufficient conditions for a set of parameters to provide a reparam-
eterisation. A simple method for determining identifiable parameter groupings
based on the nullspace of the Jacobian matrix has been presented. A reparam-
eterisation of the system is obtained by performing a state space transformation
which converts the system into a form in which only identifiable parameter group-
ings occur. It is then a relatively straightforward procedure to reparameterise the
system. As the method is based on the Taylor series approach it is applicable to
linear and nonlinear systems and also to systems with specified inputs. In order
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to calculate the minimal form of the system it is necessary to know the rank of
the infinite Jacobian matrix. To determine if the rank of the infinite Jacobian
matrix is rank deficient by (at least) 1 this is accomplished in two parallel steps:
1) the system is shown to be unidentifiable (e.g. by employing, say, the Similarity
transform approach). Hence the Jacobian matrix must be rank deficient by at
least 1 (by Pohjanpalo's rank test). 2) a subset of the infinite Jacobian matrix
is shown to be rank deficient by 1 . Hence the infinite Jacobian matrix is rank
deficient by 1. In cases where the rank of the Jacobian is further deficient it may
only be possible to get a lower bound on the rank of this matrix. The difficulty
arises from the fact that there is no theoretical bound on the number of Taylor
series coefficients which need to be considered in order that the Jacobian matrix
has maximal rank. Other constraints, such as Vajda's result [63], for linear sys-
tems, may also prove useful in determining the rank of the Jacobian matrix. To
reparameterise the system, identifiable parameter combinations are established
via examination of the nulispace of the Jacobian. Then a state space transfor-
mation is searched for such that the resulting system's parameters only occur in
identifiable groupings. It should be stressed that the reparameterisation obtained
is not unique. Although a state space transformation is usually required this is
not always the case, as in Example 2. By performing the reparameterisation a
more valjd model is. obtained for the experiment considered. The reparameterised
model is locally identifiable, by the theory given, and in addition may be globally
identifiable.
Chapter 5
Modelling of Labelled Tracer
Metabolites in Plasma
5.0.1 Overview
This chapter investigates the metabolism of two ligands used in PET brain scan-
ning to measure receptor binding; [ 11 C]diprenorphine and [' 1 C]flumazenil are
markers for the opiate receptor and benzodiazepine site, respectively. Changes
in density or affinity of these receptor systems may be important for the study of
addiction, neurological and psychiatric disorders [88] [89] [90]. Both these com-
pounds produce radiolabelled metabolites, which being polar contribute to the
total blood but not the cerebral radioactivity as they do not cross the blood
brain barrier. Two different approaches for the correction of signal from tracer
metabolism are considered. The first involves defining an arbitrary functional
form that describes the fraction of labelled metabolite in plasma and the second
approach employs a compartmental description of the underlying metabolism.
5.0.2 Introduction
Quantification of parent drug in a tissue of interest requires correction for metabo-
lites. The majority of PET tracers produce labelled metabolites in the body,
thus accurate methods for metabolite correction are required. Two situations are
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observed:-
1. Only the blood data contain a signal due to labelled metabolites, as in
Figure (5.1). Typical examples of this situation are [ 11 C}flumazenil and
[' 1 C]diprenorphine brain studies, in which the metabolites are too polar to
cross the blood brain barrier at a significant rate and the tissue signal is
dominated by the parent drug.
2. Both the tissue data and blood data contain labelled metabolites, a typical
example being [' 1 C]thymidine uptake in tumours. This case is considered
in Chapter 9. (Figure 5.1).
Plasma	 Tissue of Interest
Brain Scan
e.g. Flumazenil,
Diprenorphine
P M
M'
P M
P P
PP
P
Body Scan	 M
	
MM
e.g. Thymidine	 Mp	 pP
5-Fluorouracil	 M	 M
P = Parent
	
M = Metabolite
Figure 5.1: Metabolite distribution
It is known that both [' 1 C]diprenorphine and [11 Cjflumazenil fall into the first cate-
gory. Sadée et al [91] have shown that 1 hour after the injection of ["C]diprenorphine
at least 90 % of the label in brain is attributable to the parent compound. Simi-
larly the metabolites of [11 C]flumazenil make a negligible contribution to the total
label signal in the brain [92] [93].
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5.0.3 {11C]Diprenorphine
['1C] Diprenorphine is a PET ligand that binds to 1u-, 8-, and i-opiate receptor sub-
types with similar affinities for each [94]. One way to quantify the parameters spe-
cific to the binding of [11 C]diprenorphine in brain requires a metabolite-corrected
plasma [11 C]diprenorphine input function. However two radiolabelled metabolites
that can be detected in plasma using solid phase extraction followed by HPLC
[24] are produced by the liver. Previous methods of correcting [11C]diprenorphine
plasma time courses have involved fitting an arbitrary functional form to the
metabolite data, and then to interpolate and extrapolate the fitted metabolite
fraction to correct the plasma input function for metabolites over the whole time
course of the scan [95].
5.0.4 {11C]Flumazenil
Quantitative analysis of the volume of distribution of the central benzodiazepine
receptor in vivo also requires the determination of the unmetabolised radioligand
in plasma[86]. Liver metabolism [96] [97] of [N-methyl- 11C]flumazenil however
leads to the formation of the free acid, Ro 15-3890, and the alcohol, Ro 15-4965
[98] [99]. Indeed HPLC analysis of plasma samples indicates the presence of three
metabolic products, two of which are expected to be the alcohol and the free acid.
All the peaks are more hydrophyllic than the parent compound. Previous methods
for correcting [11 C]fiumazenil plasma time courses for the presence of metabolites
have involved the fitting of an exponential functional form [83] [48] [100].
5.0.5 Plasma Metabolite-Corrected Input Functions
The main processes involved in calculating a plasma metabolite corrected input
function are shown in Figure (5.2). This modelling scheme also indicates that the
blood data are combined with the tissue data to calculate tissue specific functional
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Figure 5.2: Modelling scheme
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parameters. The modelling of the blood data can be split into two parts;
• Obtain a continuous time course for the concentration of total label in
plasma.
• Obtain a continuous time course for the parent compound in plasma.
The temporally sparse metabolite data are a major problem in the creation of an
accurate metabolite-corrected plasma input function. This is one of the weakest
links in the overall modelling of PET data, see Figure (5.2) since the fraction
of labelled metabolites in a plasma sample is normally measured oniy at 5 or 6
time points for a ligand scan usually lasting 60-120 minutes. Metabolite data are
limited by the length of time required for HPLC analysis since the concentrations
are very small and an accurate sensitive measure is thus required. To overcome
the sparsity of the metabolite data, some form of model is required to interpolate
and extrapolate the data and provide a continuous measure of the fraction of
metabolites in plasma.
5.1 Methods
An on-line measuring system which allows for the collection of discrete blood
samples was used to record the concentration of label in blood [22]. Measurements
of the counts in whole blood were taken over one second intervals. This temporal
resolution is especially important at the start of the scan to enable the delineation
of the rapidly changing arterial blood curve. Separate analysis of the discrete
blood samples was also carried out to calibrate the radioactive counts (n=5), to
measure the relative amounts of parent and metabolite (n=5) compounds in the
plasma and the distribution of counts between plasma and red cells (n=5). The
technique of HPLC was utilised to give chemical resolution of these discrete plasma
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Figure 5.3: Whole blood constituents
samples (for details see Luthra et al. [24]). Hence, the measurements obtained
were:
. A second by second measurement of the total arterial blood radioactivity
collected on-line from the subject under investigation calibrated separately
in a well counter. ( 4aCi/ml Blood)
• A measurement of the distribution of counts between plasma (obtained by
centrifugation) and whole blood taken at various time points during scan-
ning.
• A measurement of the metabolite fraction in plasma, obtained by HPLC
analysis of discrete blood samples taken at various time points during scan-
ning.
In addition the haematocrit, Hct , was measured in some cases, (the fraction of
the blood which is made up from red cells, see Figure (5.3)). The haematocrit as
measured will be a slight over-estimation due to entrapped plasma. The presence
of white cells is ignored since their volumetric component is less than 1 percent.
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These assays allow the conversion of whole blood activity to plasma activity using
the following equation,
Plasma (t) = pbr(i)WB(t)	 (5.1)
where,
Plasma(t) : concentration of tracer in plasma
WB(t)	 concentration of tracer in whole blood
pbr(t)	 : Ratio of counts in 1 ml of plasma to counts in 1 ml of whole blood
To create a continuous function for the ratio of counts in plasma to whole blood a
function was fitted to the discrete data obtaining a least sum of squares solution.
Normally the plasma to blood ratio, pbr(t), can be represented by a straight line
or an exponential function [95] [101] (cited in [44]). Examples for the ligands
diprenorphine and flumazenil can be seen in Figures (5.5) and (5.6), respectively.
5.1.1 Preliminary Processing of Blood Data
The whole blood arterial time course was corrected for flushing periods, which
occur when the arterial line is flushed with saline, and background radioactivity.
These processes are independent of the ligand used.
Removal of Flushing Periods
Every 15-20 minutes the continuous counting of blood data is stopped while the
tubing which connects the radial artery to the BGO detection system is flushed
with heparinised (an anticoagulent) saline to prevent clotting in the system. This
results in the loss of data for approximately 15-30 seconds. The data for these pe-
riods is extrapolated by manually selecting the beginning and end of each flushing
period on the continuous blood radioactivity counts plot. A straight line was then
fitted through a small portion of the data prior to and post flushing (normally
about 15 seconds each side) by means of linear regression (see Figure 5.4).
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Figure 5.4: Section of whole blood curve
Background Correction
Background may be removed from the blood curve by subtracting the mean of the
pre-injection value of the blood curve. The background correction must be done
before any decay correction, otherwise the resulting blood curve is incorrect. This
method of background subtraction provides a reasonable correction and effective
lead shielding of the blood counter reduces this problem. However, the true back-
ground is a function of time and will depend on the activity distribution in the
subject. If this correction is inaccurate the tail of the curve for long scans (-.2hrs)
will start rising when decay correction has been applied, although this was not
observed for the studies corrected in this way.
Calibration
The on-line blood detection system was cross-calibrated using discrete blood sam-
ples taken from the arterial line and counted in a sodium iodide well counter, which
is regularly calibrated with germanium sources of known activity
Interpolation and Extrapolation of the Plasma to Blood Ratio
Plasma to blood ratios from for all the [' 1 C]diprenorphine scans are illustrated in
Figure (5.5). A linear fit (equation (5.2)) was found to produce a better fit to the
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Figure 5.5: Plasma to blood ratio for the cohort of [11 C]diprenorphine scans
data than an exponential approach to a constant.
pbr(t)	 a + /3t	 (5.2)
The mean and standard deviation for the parameters in (5.2), calculated over all
available studies, was a = 0.990 ± 0.112, and /3 = 1.27€ - 05 + 1.79€ - 05.
Plasma to blood ratios from the set of [11 C]flumazenil scans are shown in Figure
(5.6). The plasma to blood ratio was fitted with an exponential function pbr(t),
pbr(i) = a (i - €_/3t) + 1	 (5.3)
The exponential function produced a better fit to the data than the linear fit.
The mean and standard deviation for the parameters in (5.3), calculated over all
available studies, was a = 0.434 + 0.0778, and /3 = 0.00290 ± 0.000780.
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Figure 5.6: Plasma to blood ratio for the cohort of {' 1 C]flumazenil scans
5.2 Results
5.2.1 ["C]Diprenorphine
A cohort of 72 [ 11 C]diprenorphine data sets was used to examine the accuracy of
the different methods of metabolite correction. The mean metabolite fraction for
the cohort (E 1 s.d.) is shown in Figure (5.7).
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Figu 5.7: Metabolite data for the cohort of [' 1 C]diprenorphine scans
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Functional Forms
Observation of the metabolite measurements shows that a saturating function is
required to describe the metabolite fraction as a function of time. A number of
saturating functions were applied to investigate which describes most accurately
the measured metabolite fraction (see Table (5.1)). Characteristics of each of
these functions can be visualised in Figure (5.8).
Model 1 Exponential	 a (i -
Model 2 Rectangular Hyperbola
Model 3 Sigmoid
Table 5.1: Functional forms for the metabolite fraction
Figure 5.8: Functional forms for the metabolite fraction
The exponential model has been used previously to correct for the presence of
labelled metabolites in plasma [95] [102] [83] [48] [100].
The functions were fitted to the available metabolite data (equal weighting was
employed) by a simplex optimiser that attained the least sum of squares solution
[103]. The results are given in Tables (5.3-5.6).
To determine which of the models provides the best segmentation of the plasma
input function, the residual sum of squares was considered. This is sufficient
because all models have the same number of degrees of freedom. It was decided
5.2 Results	 82
35
30
25
20
15
10
S
0
Exponential Hyperbola
	
Sigmoid
Figure 5.9: Number of studies producing best fit for [11C]diprenorphine
that the best model would be the one which produced the smallest sum of squares
most consistently. Figure (5.9) shows for each function the number of studies for
which it produced the best fit. The exponential form for the metabolite fraction
produced the best results followed closely by the hyperbolic function, with the
sigmoid function giving the least satisfactory results.
Since a simple exponential function best described the metabolite data, this sug-
gested that a simple compartmental structure could be used to describe the
metabolism process.
Compartmental Metabolism Model
The simplest compartmental model for describing the metabolism of a compound
is illustrated in Figure (5.10). This is a simplification of the body's complex
metabolic system but it describes the important factors; the metabolite is cre-
ated at a rate proportional to the concentration of the parent in plasma and the
metabolite is eliminated from the plasma at a rate proportional to the concentra-
Whole Body
Clearance
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Figure 5.10: [fl CJ Diprenorphine metabolism model
tion of metabolite in plasma. The model illustrated in Figure (5.10) is described
by the following differential equation,
dt	 k1P(t) - (k2 + A) M(t)	 (5.4)
The system variables are defined by,
T(t) - Total plasma concentration
P(t) - Parent plasma concentration
M(i) - Metabolite plasma concentration
Mf(t) - Metabolite fraction in plasma
The parameter A represents the decay of the radioisotope and is a known pa-
rameter. The model as postulated does not restrict the metabolism to occur in
the plasma; the metabolism will also occur in the body's metabolising tissues
(principally liver). The effective transfer rate between the tissue compartment
and plasma is assumed to be fast and this allows a tissue compartment to be
neglected.
Equation (5.4) is solved to give the metabolite concentration as a function of the
parent concentration,
M(t)	 kie('c2')i ® P(t)	 (5.5)
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where ® represents the convolution operator. The following are deduced from the
variable definitions.
T(t) = P(t) + M(t),	 (5.6)
Mf(t) = T(t)	 (5.7)
Equation (5.5) can be transformed to give the metabolite fraction Mf(t) in terms
of the total plasma concentration T(t). Eliminating P(t) from equation (5.5)
gives,
M(t) = k16(k2+A)t ® (T(t) - fiv[(t))	 (5.8)
Taking Laplace transforms yields
k1 _________
	 (5.9)
which, after rearrangement, gives
k1
	\	 k1
or
lcr= (
_s+k2+	 \ Ik1
\s+ki+k2+A)
Hence
\s + k1 + k2 + ))
and taking inverse Laplace transforms gives,
(5.10)
(5.11)
(5.12)
.11/1(t) = k	 i+k2+))t ® T(t),	 (5.13)
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Figure 5.11: Fit and metabolite contribution for p02447 (['1C]diprenorphine)
Thus the metabolite fraction Mf(t) is given by
- kie_(d1+k2 )t ® T(t)
Mf(t) -
	 T(t) (5.14)
Examination of equation (5.12) reveals that both k1 and k2 are uniquely (globally)
identifiable (via the Laplace transform approach). The fitting procedure involves
obtaining 2 parameter values from 5 observations. Figure (5.11) illustrates a
typical fit to the metabolite fraction, the second and third graph showing the total
plasma activity and the metabolite contribution. The plasma metabolite-corrected
input function is simply obtained by subtracting the metabolite component from
the total plasma activity. This technique of manipulating the equations allows the
metabolite component to be described as a function of the known total plasma
activity. This approach has been used by Huang et al. [104] to describe the
conversion of the injected tracer to its metabolites for [18F]fluoro-L-dopa and 1502.
Tables (5.3-5.6) list the parameter values and residual sums of squares for the
different models. The fitting of the compartmental model is robust and little cor-
relation between the two parameters is observed (correlation coefficient : mean
0.8770 ± 0.0539sd) (ranging from .625 to .965). Thus this demonstrates that the
model parameters are numerically identifiable. The distribution of the parameter
io_3
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Figure 5.12: Histograms of parameter values for all studies
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Figure 5.13: Plot of parameter values against scan number
values k1 and k2 obtained for all the studies is displayed in Figure (5.12). Both
parameters appear to be approximately normally distributed apart from a group
of outliers. After further investigation of various factors (patient age, weight, con-
dition, clinician, study no.) the outliers were found to correspond to a particular
period in time. This was indicated by the study number which lists the scans in
chronological order 	 no. 2000).
The parameter values are plotted against study number in Figure (5.13). It is
likely that an error had occurred in one of the measuring systems. One possible
explanation is that a faulty column was installed on the HPLC system. Once the
scans around this period have been removed the parameter distributions appear
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Figure 5.14: Histograms of parameter values for reduced set of studies
to be approximated by a normal distribution, see Figure (5.14).
5.2.2 Discussion
An important feature of these models is the ability to extrapolate the data well
after the final data point, especially for the case where no late metabolite data
exists. This fact is implicit in the functional forms which are all saturating func-
tions, and effect an asymptote which is determined reasonably accurately from
just the early time points (up to 1800 seconds). The compartmental model also
handles the extrapolation effectively with the model tending towards an equilib-
rium in which the distribution between parent and metabolite is a constant factor
which is determined by (k1k2)' and these values can be seen in Tables (5.5-5.6).
The advantage of using the compartmental approach is its flexibility in dealing
with different forms of input and its parameter values having a more physiolog-
ical interpretation. When the injection does not approximate a bolus the corn-
partrnental approach is more applicable, relying on an underlying physiological
model rather than the arbitrary functional forms. In conclusion the metabolism
of [1C]diprenorphine can be adequately accommodated in terms of a simple pre-
cursor product relationship. This is not the case for the next example.
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5.2.3 [11C}Flumazenil
The blood curves obtained from ["C]flumazenil scans suggests the presence of
metabolite by exhibiting a non-monotonic decrease from the peak plasma radioac-
tivity, see Figure (5.15). It was hypothesised that this bump may give important
IIme(sec.)
Figure 5.15: Typical [11 C]flumazenil whole blood time activity curve
information about the metabolism in the system. Inspection of the metabolite
fraction indicated a delay in the production of metabolites (see Figure(5.16)).
This delay being the key factor which causes a bump to appear in the blood
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Figure 5.16: Metabolite data for the cohort of [11 C]flumazenil scans
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curve. The inherent delay implies an apparently more complex model than the
one used for [ 11 C]diprenorphine. The delay was approximately 90 seconds and
this was established by inspection of metabolite time course data obtained from
plasma samples. A cohort of 32 ["C]fiumazenil studies was considered to evaluate
the effectiveness of a series of postulated models for metabolite correction. The
mean metabolite fraction for the cohort (± 1 s.d.) is shown in Figure (5.16).
Initially the metabolite data were fitted to the functional forms used previously,
(5.1), with the addition of a delay term. The results of fitting the functional forms
are listed in Tables (5.7-5.8). The exponential function again proved to be the
most successful approach and this is demonstrated in Figure (5.17).
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Figure 5.17: Number of studies producing best fit for ['1C]fiumazenil
Compartmental Metabolism Model
System identification of an appropriate metabolism model is more readily achieved
by examining the metabolite as a function of parent. Examination of possible
models was initially investigated by segmenting the plasma curve into parent and
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Figure 5.18: [11 C]Flumazenil metabolism model
metabolite time courses (using the exponential functional form). It was discovered
that the simple model used previously was insufficient to describe the metabolism
of ["C}flumazenil. A more comprehensive metabolism model, including the addi-
tion of a tissue compartment for metabolism, was thus chosen (Figure (5.18)). The
observed •
 delay in the formation of metabolite also necessitated the introduction
of a delay term in the model.
Segmentation of the plasma time activity curve produces a parent in plasma time
activity curve P(t) and a metabolite in plasma time activity curve M(t). These
two functions were fitted to the equations derived from the compartmental model
illustrated in Figure (5.18). This model describes the exchange of parent drug
between plasma and the body's metabolising tissues (principally liver), the elim-
ination of compound from this tissue and the transfer of metabolite from the
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metabolising tissue back into plasma. The model includes a delay ,S, and A repre-
sents the decay of the isotope, with a known value. The following set of ordinary
differential equations describes the system,
dT(t)
dt
dM(t)
dt
= kiP(t - S) (k2
 + km + A)T(t)
= kmT(t) - (kern + A)M(t)
(5.15)
where
P(t)
T(t)
M(t)
k2
km
kern
- Parent plasma concentration
- Metabolising tissue concentration
- Metabolite plasma concentration
- Rate constant for transfer of parent from plasma to metabolising tissue
- Rate constant for transfer of parent from metabolising tissue to plasma
- Rate constant for transfer of metabolite from metabolising tissue to plasma
- Rate constant for elimination of metabolite from plasma
- Decay constant (0.0005663 sec')
Identifiability and Reparameterisation
Identifiability analysis and a subsequent reparameterisation was performed on
the system (5.15) using the methods presented in the previous chapter. The
identifiability analysis was performed using the Taylor series method. Without loss
of generality, A is set to 0 for the identifiability analysis and the reparameterisation,
and it is readily reintroduced at the end. The first 3 Taylor series coefficients of
the observation evaluated about 5 are given by;
(l) (+) = kikm
(2) (+) = ki km ( kem + k2 + km)
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(3) (s+) = ki km(k + 2k2 km + k2 ' k2
 + k2 kem + km kern)m em
(5.16)
The Jacobian matrix defined by the partial derivatives of the Taylor series coeffi-
cients with respect to the parameters is,
km	 0	 k1	 0
G(O°) =
	 km (k2
 + kern + km)	 ki km —k1 (k2 + kern + 2km )	 kikm
Cl	 C2	 C3	 C4
(5.17)
where
C1 km (k2 + km) 2 + kern km (k2 + kern + km)
C2=kikm(2k2+kem+2km)
C3 = k (k + k2 kem + k m + 4k2 km + 2kem km + 3k)
C4
 = ki km (k2 + 2kern + krn).
(5.18)
The infinite Jacobian matrix, G(9°), can be shown to have rank less than or
equal to 3 by considering the transfer function for M when Laplace transforms
are applied to (5.15) yielding,
k1 km
M=
	
	 P	 (5.19)(s + kern)( + k2 + km)
It can readily be seen that the 4 parameters k1 , k2 , krn, kern are combined together
in just three coefficients in the transfer function. Therefore G(O°) can have, at
most, rank 3. By considering the rank of (5.17) this implies that G(O°) has rank
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equal to 3.
To calculate the identifiable parameter groupings it is necessary to consider the
nulispace of the Jacobian matrix (5.17). The nulispace is spanned by,
= {__, —1, 1, 0}	 (5.20)
Applying Theorems 2 and 3 enables the calculation of identifiable parameter
groupings from
< D(9°),n> = 0.
	 (5.21)
The simplest identifiable parameter groupings are
{kem , k2
 + km, kikm}
N.B. It should be noted that these identifiable parameter groupings are also readily
established from the transfer function defined in (5.19). A suitable state space
transformation can be obtained by making the following substitution for the state
variable T in equation (5.15),
T* kmT.	 (5.22)
This yields the following state space transformation for the system which provides
a locally identifiable reparameterisation.
= -
M=T*_3M
(5.23)
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where q i ki km, q = k2 + km, and	 kern. The parameter A may readily be
reintroduced to obtain the true reparameterisation of system (5.15), given by
1* = i P -
M=T*43M
(5.24)
where i = ki km, q = k2 + km + A, and q 3 = kem + A. This system is then solved
using the method of Laplace transforms, i.e. taking transforms of (5.24) gives
ST*lP_ç2T*
.sM=T*_3M,
(5.25)
whereby
M= T*
S +
*_
.9 + 2
(5.26)
and solving for M gives
M= (s + 3)(S+ '72)
(5.27)
By employing the inverse Laplace transformation,
M(t) = { 0 , (- i
 - est) 0 P(t - ) (5.28)
The data were then fitted to this equation using a simplex optimiser to obtain the
least sum of squares fit, data being weighted as the reciprocal of the dependent
variable.
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Fitting of Model to Metabolite Data
The next step was to rearrange this model in terms of the total plasma activity.
There is no explicit solution for the metabolite fraction in terms of the total
plasma activity because of the delay in the model, thus a novel fitting procedure
was proposed.
Iterative Method
The delay in the production of the metabolites averages approximately 90 seconds
and so the initial part of the plasma curve is simply parent drug. This measure
of the initial amount of parent compound allows the employment of an iterative
procedure to calculate the full time courses of parent and metabolite. Given a
set of parameter values and numerically convolving the initial parent concentra-
tion with the metabolism model provides the initial, delayed, metabolite signal.
This metabolite signal is then subtracted from the subsequent total plasma con-
centration to give the second segment of parent concentration. This procedure is
repeated, calculating the parent and metabolite concentrations in segments whose
lengths are equal to the delay. The parameters for the metabolite model are op-
timised using a simplex method until the metabolite fraction best represents the
measured fraction, in a least sum of squares sense. Each data point is weighted
equally. The iterative scheme was found to be robust for delays that occur with
[il Ciflumazenil's metabolites (50 - 200 seconds).
It was necessary to fit for the delay in formation of the metabolite. This process
could not be included easily in the parameter fitting routine because the total
plasma curve is sampled every second and this would mean that the total plasma
curve would have to be resampled every iteration. This problem was eliminated
by employing a golden ratio search [105], on top of the simplex fitting routine to
find the delay that minimised the residual sum of squares. A typical fit is shown
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in Figure (5.19) and the results are listed in Tables (5.7 and 5.9).
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Figure 5.19: Fit and segmentation for n00296 ([liCiflumazenil)
5.2.4 Discussion
Prediction of the metabolite component from the non-monotonicity in the curve
is very difficult because to fit to solely the total plasma time course, a functional
form for the parent is required. Any functional form for the parent requires many
parameters [106], and coupling this with the four parameters in the metabolism
model, any subsequent fitting becomes unfeasible.
5.2.5 Partition Coefficient Model
Inspection of the plasma to blood ratio revealed that there was a simple rela-
tionship with the metabolite fraction, see Figure (5.20). This indicated that the
parent and metabolite components had significantly different partition coefficients
between red cells and plasma. The correlation coefficient for the metabolite frac-
tion and the blood to plasma ratio was significant at the 5% level for 21 of the 32
studies, see Figure (5.21). For the studies in which this correlation was not signif-
icant the plasma to blood ratio measured at the late time point (' 5000 secs) was
different from the equilibrating trends of the previous points. This suggested that
1.
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Figure 5.20: Plot of blood/plasma partition and metabolite fraction
the assay of the blood samples at later times was inaccurate, and that the samples
should have been counted for a longer period (see Discussion that follows).
—1	 -.0.9	 —0.8	 —0.7	 —0.6	 -0.5
Correlation Coefficient
Figure 5.21: Correlation coefficients for a cohort of 32 scans (blood/plasma vs
metabolite fraction)
Model
A linear relationship as seen in Figure (5.20) was therefore predicted. At equilib-
rium, the partition of parent [' 1 C]flumazenil and its labelled metabolites between
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plasma and red cells can be considered to be:
PLPar(t)a = Rc.Far(t)
Plit/let(t)/3 RcJVIet(t)
(5.29)
Concentration of label in plasma	 P 1(t)
Concentration of label in red cells 	 Rc(t)
Concentration of label in blood 	 W1(t)
Fraction of rnetabolite in plasma	 Mf(t)
Haematocrit	 h
Concentration of parent in plasma	 PLPar(t)
Concentration of metabolite in plasma PlJVIet(t)
Concentration of parent in plasma Rc_.Par(t)
Concentration of metabolite in plasma Rc_Met(t)
Partition coefficient for flumazenil
Partition coefficient for metabolites	 /3
Table 5.2: Parameters for partition coefficient model
The variables used in the model postulated are given Table (5.2). The metabolite
fraction, the concentration in plasma and the concentration in red cells are defined
by
Flit/let (t)Mf(t) = P1(t)
P1(t) = PLPar(t) + PlJVlet(t)
Rc(t) = RcPar(t) + RcMeL(t)
(5.30)
Given these definitions one can proceed to derive a linear relationship between
the metabolite fraction and the whole blood to plasma ratio.
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Since
Wl(t) = hRc(t) + (1 - h)Pl(t)	 (5.31)
using (5.30) this gives
W1(t) = h(Rc...Par(t) + RcJ[et(t)) + (1 - h)(PLPar(t) + P1Jk[et(t))
= h(aPLPar(t) + /3P1JVIet(t)) + (1 - h)(PLPar(t) + PLMet(t))
Pl(t)(1 - h + ah) + h(j3 - a)Pl_Met(t)
(5.32)
Dividing through by P1(t) yields
Wl'(t)
= (1 - h + ah) + h(/3 - a)Mf(t)	 (5.33)
P1(t)
or
Mf(t) - W1(t)	 1	 1 - h + ah (5.34)
P1(t) h(/3—a)	 h(/3—a)
Model Results
For the (32) data sets considered, time points were chosen which comprised both
a whole blood to plasma ratio and a metabolite fraction, producing data sets
containing between 3 and 5 data points. These data sets were fitted to equation
(5.34) using a measured haematocrit value (1 to 17) and a standard hameatocrit of
0.4 when no haematocrit was measured (18 to 32). The parameter values obtained
for the partition coefficients a and ,8 are listed in Table (5.10) and histograms of
the parameters are illustrated in Figure (5.22).
Examination of the histograms reveals that the partition coefficients a and are
approximately normally distributed with mean values of 0.84 and 0.036 respec-
tively. The significance of this result is the distribution of the metabolite, which
is predominantly in the plasma (96% of metabolite in plasma).
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Figure 5.22: Histograms of calculated partition coefficients
At first a number of the fitted values for 3 were negative, which is physiologically
impossible, hence the model was refitted fixing /3 and allowing a and h to vary.
This process was repeated, varying /3 each time, until the fitted values for h
most closely matched the measured h in a least squares sense. This process was
carried out for data sets in which the haematocrit had been measured. A value
of /3 = .036 minimised the difference between the haematocrits, see Table (5.11).
The correlation between the two haematocrits can be seen in Figure (5.24) and
the correlation coefficient was 0.77. A histogram of the a and h values for all the
studies with /3 = .036 is shown in Figure (5.23).
Figure 5.23: Histograms of fiumazenil partition coefficients and haematocrits
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Fitted Haematocrit
Figure 5.24: Correspondence between measured and calculated haematocrit
5.2.6 Prediction of Metabolite Data
The data sets were investigated to see if early metabolite and plasma to blood
ratio data could be used to predict the late metabolite points simply from the
plasma to blood ratio. A typical example can be seen in Figure(5.25) where the
predicted values are 0.5% and 5.4% different from the measured values. This
prediction was applied to all the studies and the percentage error was calculated
for the final data point. It was found that 62.5% of the studies were within 10%
error at this time point. Inspection of the data again emphasised the need for
more accurate measurement of blood data towards the end of the scan.
5.2.7 Discussion
To summarise, two results have been obtained. Firstly, the accurate correction of
the [' 1 C]flumazenil blood input function for metabolites has been achieved using
a compartmental model. Secondly, a partition model has been applied to the
plasma/blood data to produce additional metabolite measurements. A novel pro-
posal for the accurate creation of a metabolite corrected plasma input function
for [11 C]flumazenil is summarised by Figure (5.26). The proposed scheme involves
collecting more plasma to blood partition data later in the scan and counting the
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Figure 5.25: Prediction of late metabolite data using blood/plasma data and
partition model
samples for a much longer period to increase accuracy. This data in conjunction
with the partition model will then allow for the creation of accurate metabolite
data later in the scan. This process is less complicated than the HPLC procedure
and it is predicted that it will be more accurate at these late time where the HPLC
method is inaccurate due to the very small concentrations of parent and metabo-
lites. The plasma to blood ratio is interpolated with an exponential function and
multiplied with the continuous blood radioactivity time course to create a total
plasma radioactivity time course. Finally the compartmental model, shown ear-
lier, is applied to the composite metabolite data to create a metabolite corrected
plasma input function. This proposal would involve no increase in complexity of
the blood analysis, the metabolite analysis being the most laborious step, and it
is hypothesised that a more accurate metabolite correction would be obtained.
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Figure 5.26: Proposed method for metabolite correction of [11 C]fiumazenil blood
data
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Table 5.3: Diprenorphine metabolism model results
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Table 5.6: Diprenorphine metabolism model results
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Table 5.7: Flumazenil metabolism model results
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Table 5.9: Flumazenil compartmental model parameter values
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Table 5.10: Calculated partition coefficients for ["C]flumazenil and metabolites
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Table 5.11: Calculated partition coefficient for ["Cjflumazenil and haematocrit
Chapter 6
Spectral Analysis
6.1 Overview
This chapter contains an introduction to spectral analysis and its implementation.
A novel proof is presented that shows that the problem is well defined. This
proof may also be interpreted in an identifiability framework and, as such, gives a
sufficient condition for a uniquely (globally) identifiable solution. To understand
the solution of the problem more fully, the nonnegative least squares algorithm is
considered in conjunction with the Kuhn Tucker theorem [107]. Novel extensions
of the basic method involving different basis functions and multiple inputs are
investigated. These methods of spectral analysis are applied to the tracer kinetics
of carbon dioxide and thymidine in Chapters 8 and 9.
6.2 Introduction and Background
Spectral analysis is a kinetic modelling technique that lies between the strictly
data-led and highly structured methods. It is based on the a priori definition of a
relatively large set of basis functions which are used in the fitting of PET data, the
fit consisting of a small subset of these. Spectral analysis is the least structured
technique to employ an input function (see Figure 3.2 in Chapter 3) and gives
113
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quantitative measures of physiological parameters, e.g. K 1 , VD etc. The method
is based on a constrained linear optimisation problem and is a further development
of an approach used by Tobler and Engel [108], who used a set of hyperbolic
basis functions to investigate in vitro binding data. Cunningham and Jones [34]
chose a set of exponential functions convolved with the plasma input function
to form a set of basis functions facilitating the analysis of PET tissue data. The
choice of exponential basis functions stemmed from the theory of first order tracer
kinetics. Most linear compartmental structures used for the analysis of PET data
produce a series of first order differential equations whose solution is a sum of
positive exponentials. (Note that the original assumption by Cunningham and
Jones [34] that all first order tracer kinetic models satisfy a nonnegative sum of
exponentials is incorrect. Cases exist which have negative coefficients and others
with repeated eigenvalues). Components are obtained by fitting a large set of these
basis functions to the tissue time activity curves with suitable system parameter
constraints. The linear optimisation problem is however highly underdetermined
and a constraint is essential to construct a robust framework, see Figure (6.1).
The technique employs a nonnegativity constraint that makes the problem well
defined (see section 6.4). This chapter considers why constraints are required and
how they ensure that the problem is well defined. Spectral analysis can be con-
sidered as a constrained deconvolution technique that avoids the problems that
many direct deconvolution techniques encounter in the presence of noisy data. By
deconvolving the input from the observed tissue signals, variations due to differ-
ent types of injections and plasma characteristics are removed and the resulting
function becomes a plasma independent measure of the tissue's behaviour. Since
the deconvolution process is badly determined, the method of spectral analysis
produces a more robust deconvolution by restricting the possible deconvolution
to a nonnegative sum of exponentials. This, by definition, forces the impulse
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Non-Negative Least Squares (NNLS) Problem
1 xN	 MxN	 lxM
b=Ax
2
	
m;nimize	 Ax -b	 subject to x1>O
Figure 6.1: The matrix problem
response of the system to be a monotonically decreasing function. The basis func-
tions are chosen so that they span all possible dynamics from fast blood effects to
irreversible binding.
Once a solution has been obtained from the spectral analysis process the spectrum
of chosen exponentials may give important kinetic information about the system
(Figure (6.2)). The various components can be interpreted to give an understand-
ing of the physiological, pharmacological and biochemical processes involved. Fast
kinetics wjth a large 9 value correspond to blood effects, intermediate kinetics to
reversible kinetics, and slow kinetics to irreversible kinetics of the tracer.
Lack of structure restriction by the method results in the obtained spectra hav-
ing a number of possible interpretations. This refers to the problem of indistin-
guishability of models. For example, the method will not distinguish between two
parallel or catenary compartments, both of which contain an indistinguishable
sum of positive exponentials. However since both systems have an equal volume
of distribution determined by the area under the tissue response function extrap-
Component
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a
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Figure 6.2: Spectrum interpretation
olated to infinity, VD is a robust parameter estimate independent of structural
interpretation. The method is a good process for investigating appropriate model
order.
Spectral analysis has been applied successfully to PET data [34] [35], although
there is a problem as to whether the solution obtained is unique. A condition
for uniqueness is presented in section 6.4 . The non-negative least squares algo-
rithm used to solve the problem is presented and discussed in the context of the
Kuhn Tucker Theorem which guarantees that a local minimum is obtained on
termination of the algorithm.
6.3 Methods
The method of spectral analysis involves finding a solution to the problem (as in
Figure(6.3)),
PETol.s(tk) = Input(t) ®
	
(6.1)
given ic E {1, 2, ..., N} and the non-negativity constraint a 	 0, aj
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Figure 6.3: Spectral analysis
The /3's are chosen in a logarithmic range and n > N. In practice n = 100 is
found to be an acceptable number providing a good kinetic resolution. The values
for /3 are normally chosen in a logarithmic range so that the linear dependence
between the basis functions is similar.
6.3.1 Functional Parameters
Key characteristics of a system can be obtained by various manipulations of the
impulse response function. The delivery rate constant, K 1 , of the compound cor-
responds to the intercept of the impulse response at t = 0 in the absence of blood
volume and dispersion. The area under the impulse response function extrapo-
lated to infinity equals the volume of distribution in the tissue of interest. Often,
the most important measure is the volume of distribution, VD, that quantifies the
ratio of concentration of compound in tissue to the concentration of compound
in plasma which would pertain at equilibrium. The mean residence time of the
compound in tissue can be calculated as the ratio of the VD over the delivery
K1 . In ligand studies it is possible to show that the volume of distribution is
proportional to the number of available binding sites [109].
6.3.2 Non-Negative Least Squares Algorithm (NNLS)
Before considering the algorithm for NNLS [110], the method is presented graphi-
cally for the case where three data points exist. This simplification of the method
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allows us to visualise it in three dimensions, Figure (6.4). In the diagram the
vectors are the basis functions ranging from fast to slow dynamics. The circle
represents a noisy data set generated from a single exponential. If there was no
noise in this data set the circle would lie on the surface defined by the basis vec-
tors. The solution to the NNLS problem is obtained by minimising the distance
between the data point and a point in the volume defined by a non-negative span
of the basis vectors. In this case the solution is a single basis function whose mag-
nitude is given by the distance along the vector on which the data point projects
orthogonally.
NNLS Fit to Basis Functions
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Figure 6.4: Solution to NNLS problem
The nonnegative least squares algorithm [110] determines the least sum of squares
solution given the nonnegativity constraint on the parameter vector. The algo-
rithm proceeds by maximising the dual problem which corresponds to a minimi-
sation of the primal problem [110], these are given by
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Primal J = (Ax - )T (Ax - tb), x > 0	 minimise J
Dual	 - 2A(Ax - i, w < o maximise w	 (6.2)U) = --
The dual gives the derivative of the sum of squares with respect to the introduc-
tion of each component. The algorithm proceeds by calculating the dual vector,
w, and introducing a component whose dual value is a maximum. The prob-
lem is then solved for just this component and the dual is recalculated. A new
component is then introduced in the same manner. However, if at any stage the
introduction of any components causes the regular least squares fit to produce
negative coefficients, these components are eliminated such that the positivity
constraint is upheld. This process continues until the introduction or deletion of
any component can only increase the residual sum of squares. At this point the
algorithm stops and a local minimum has been found. The following algorithm is
taken from Lawson and Hanson [110].
NNLS(A,m,n,b,x,w,z,P,Z) [110]
1 SetP=q,Z={1,2,...,n},andx=0.
2 Compute the n - vector w = AT (b - Ax).
3 IfthesetZisemptyorifw < O forallj E Z, gotoStepl2.
4 Find an index t Z such that Wt max{w : j E Z}.
5 Move the index t Z from set Z to set P.
6 Let A denote the m x n matrix defined by
f' 7	 - f colttmnjof A ifjEPLoLumn2oJEip\ 0
	
ifjEZ
Compute the n - vector z as a solution of the least squares problem Az b.
Note that only the components z, j E P, are determined by this problem.
Define zj
 = 0 for j E Z.
7 If z > Oforallj E P, setx = zandgotostep2.
8 Find an index q E P such that 	 = min{ 1i .
 : zj <0,j E P}.
9 Seta=
ZgZq
10 Setx_—x+a(z—x).
11 Move from set P to set Z all indices j E P for which x = 0. Go to step 6.
12 Computation Complete.
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6.3.3 Kuhn Tucker Conditions
The NNLS algorithm terminates with a solution vector x which satisfies
	
x >0, j E P	 (6.3)
	
= 0, j E Z	 (6.4)
and x solves the least squares problem
Ax
	 (6.5)
The dual vector w satisfies
= 0, j E P	 (6.6)
^ 0, j E Z	 (6.7)
and
w_AT(1_Ax)	 (6.8)
Equations (6.3,6.4,6.6,6.7, and 6.8) constitute the Kuhn Tucker conditions [110].
The essential point is that the dual is the (negative of the) gradient vector of
the residual sum of squares, and, given that this is less than or equal to zero
no component can be introduced without increasing the residual sum of squares.
Hence in parameter space any perturbation of the solution x causes an inferior fit
and therefore x is a local minimum (for proof see [110], pg 160).
6.4 A Well Defined Problem
A problem exists concerning whether the solution obtained is unique due to the
underdetermination of the system (see Figure (6.1)). This section provides a proof
to show that the problem is well defined. The proof is based on an identifiability
framework and considers whether a given spectrum obtained from the described
form of spectral analysis is a unique solution to the problem.
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Spectral analysis concerns the solution of an underdetermined system of linear
equations. If no constraints are employed the method yields a solution which is
unidentifiable (as the number of equations is less than the number of unknowns)
and infinitely many solutions exist. However this is not the case with the intro-
duction of a non-negativity constraint. This section gives conditions such that the
problem postulated is well defined, and yields a unique solution.
To establish a condition for uniqueness the system is considered for a bolus input
and perfect input-output data. This gives rise to a problem whereby a non-
negative sum of exponentials is to be fitted to the system's impulse response
function.
n
Iri-lpulseResponse(t k) =
	
ce'	 (6.9)
i=1
given k E {1, 2, ..., N} for some N E N subject to the non-negativity constraint
6.4.1 Uniqueness of the Solution
The problem is constructed in an identifiability context and is examined for the
case where perfect data is available. The proof considers a spectrum that has been
obtained from the algorithm and determines whether this solution is uniquely
(globally) identifiable.
Brief Overview of Proof
• Lemma 1. Show that for rational 's any /3 can be constructed as the
product of a natural number and a chosen constant. The proof's restriction
to rational values for /3 is consistent with a computer implementation.
• Lemma 2. Show that number of positive real roots of a polynomial is con-
ditional on the number of sign changes in the polynomial (Descartes Rule
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of Signs).
• Theorem 4. Show that a sum of exponentials can be mapped onto a poiy-
nomial and deduce that no positive sum of exponentials can be made up
from any other under appropriate conditions. The theorem considers the
maximum number of time points for which two different positive sums of
exponentials can be equal.
The following two results will be required.
Lemma 1 Given B = {3 : E Q for i = 1,. . . , N}, then there exists
E Nsuchthat/3 = n2 &fori =
Proof Choose 6 E	 to be the greatest common divisor (GCD) for all ,8 E B.
eGCD(/3)
Hence /3	 nje for all i.
Lemma 2 Descarte's Rule of Signs [111]
Given a polynomial of the form,
a) + a_1 A 1 + ... + ai) + a0 = 0	 (6.10)
Let S be the number of sign changes in the sequence of coefficients {a, an_i, ..., a 1 , ag}
ignoring any which are zero. Then there are at most S roots of (6.10) which are
real and positive. Furthermore there are either S,S-2,S-,... positive real roots of
the polynomial.
(6.11)
6.4 A Well Defined Problem	 123
Theorem 4 Given that the impulse response is a realisation for some in <
then
7Th	 fl
(6.12)
i=1	 j=1
for any given Ic E {1, 2, ..., N}, and subject to the non-negativity constraint a, ,8, y, Sj >
0, except the degenerate solution m = n,cr = y ,13 = for alli,j.
Proof To prove the Theorem by contradiction, let us assume there exists an in <
such that,
m	 Th
ce1	 = Eyje &2tk .	 (6.13)
i=1	 j=1
Define f(tk ) by
7Th	 Th
f(tk) =	 ae_ tk -	 0	 (6.14)
i=1	 j=1
Using Lemma 1, define e E Q such that
0	 = GCD (9, 8)
and such that for all i,j
/9=n,E for somenEN
and
Sj = nje for some fl2 E N.
Let
=
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which implies that
= )(t)'	 (6.15)
eSitk =	 (6.16)
Substitution of equations (6.16) and (6.16) into equation (6. 1) yields
m	 n
f(tic)	 g(A) =
	
- > yj A (tk) i	 0	 (6.17)
i=:1	 j=1
such that for each i,j,nj,nj
 EN and so equation (6.17) is a polynomial in A.
Using Lemma , the polynomial g(A) = 0 has at most 2m changes of sign, which
implies g(A) = 0 has at most 2n-i positive real roots of the form
A(t) = e_etk
This implies that
A(tk) E
	
if and only if tk E
and
+ if and only if tj
Hence f(tic) = 0 is satisfied for at most 2m distinct values of tk
Therefore if rn < then
m	 n
ye 5'	 (6.18)
i=1	 j=1
except for the degenerate case in = n,a = 'yj,,I3i = 'y for all i,j.
Remark : This Theorem guarantees that, if a solution to the spectral analysis
problem with N data points has m components and in < then the solution is
unique.
DO
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6.4.2 Example
Flumazenil is a 11 C-labelled PET radioligand for the study of the central benzodi-
azepine site (CBZR) in humans and primates [48] [85]. In PET studies, as carried
out in the MRC Cyclotron Unit, Hammersmith Hospital, the drug is intravenously
injected for a short period (approximately 20 seconds), and during the scan the
arterial blood is sampled once a second. The arterial blood curve is converted
into a plasma activity curve and corrected for plasma metabolites (see Chapter
5) to give the input function for the tracer kinetic analysis (Figure (6.5)). The
scan contains 28 time frames of data, these frames becoming longer as the scan
progresses due to the slowing of the dynamics in the data and the loss of counts
as a result of the isotope's decay. A region of interest (ROT) is then applied to
the dynamic tissue data to obtain a time activity curve for the particular region.
The ROT used in this particular example contains 36 pixels and the ROT covers
1.45cm2 (36(2.006) 2 mm2 ). This gives us a time activity curve containing 28 data
points, i.e. N = 28.
Flumazenil input Function
time (secs)
Figure 6.5: Flumazenil metabolite corrected plasma input function
>Ca
DO
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NNLS fit obtained
time (secs)
Figure 6.6: PET data (x) and spectral analysis solution (-)
Figure (6.6) shows the spectral analysis solution to the measured tissue data and
Figure (6.7) gives the spectrum of kinetics obtained. The fitting procedure pulls
out 5 components for the impulse response function. This is effectively three
exponentials because two pairs are observed for adjacent /3 values, which is the
result of the algorithm trying to pick an exponential in between the discretised
values.
The data consists of 28 points (N) and the solution has 5 components (m), so the
inequality m < is satisfied and hence, by the Theorem, the solution is unique.
The spectrum obtained can be interpreted as a two compartment model with a
blood volume component. This is consistent with the known kinetics of fiumazenil
in the brain [109].
56.5 Extensions of Spectral Analysis	 127
Log (Beta)
Figure 6.7: Spectrum defined by the solution to the NNLS fit
6.5 Extensions of Spectral Analysis
6.5.1 Basis Functions for Displacement Studies
Flumazenil is a ligand which binds to benzodiazepine receptors in the brain and
this binding can be reduced by introducing a competing non-radioactive ligand
into the system [83]. The endogenous or exogenous ligand competes for the same
receptor type lowering the permissible binding of the radiolabelled PET ligand
and causes a decrease in the tracer's signal.
Experiments were performed using an adapted whole body gamma counter [112].
Two detectors were wired in coincidence above and below the patient's head allow-
ing for the acquisition of a whole head tissue time course. Due to the sensitivity of
the large gamma detectors and the lack of tomographic information, counts thus
being summed from the whole volume of interest (head), it was possible to obtain
highly accurate time courses for very low doses of administered radioactivity (-
8OCi). The system has a very high temporal resolution and the spatial resolu-
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tion is limited to the number of detectors [113]. High temporal resolution results
from the trade-off in spatial resolution. The head curve data is acquired every
5 seconds. Initially labelled fiumazenil is administered and, after 30 minutes, an
exogenous dose of cold flumazenil is injected to displace the signal.
Method
A representative ' 1 {C]flumazenil input function was calculated from a population
of (n=32) plasma metabolite corrected input functions (no increase in plasma
concentration was observed after displacement in similar PET studies with arte-
rial sampling). Flumazenil's kinetics in the brain can be approximated by a single
compartment with specifically bound, non-specifically bound and free ligand com-
partments all equilibrating quickly [109]. The system characteristics are allowed
to change at the time of displacement and the problem is analysed by constructing
a set of displaced basis functions, given by
BF
	 {
>ii:;'= e2it1c	 if tk < td
I2i e_k2itde_/2i(ttd) otherwise
(6.19)
where i = 1,.. . , 100 and Ic21 is chosen in a logarithmic range between the fastest
and slowest possible dynamics 1 > k21 > .0005663. In this system DF is a
displacement factor which accounts for the change in the system characteristics
and td is the time of displacement. If DF = 1 there is no displacement and the
basis set corresponds to using a set of exponentials as described earlier in this
Chapter. When DF> 1 the basis set describes a displaced system.
The system corresponds to generating a model of heterogeneous single compart-
ments, Figure (6.8). The model makes the assumption that all compartments are
displaced by the same fraction. This may not always be the case, however the
model approximates the overall behaviour of the system.
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System 1 : Pre-Displacement
Lri
Ti
T2
k22
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System 2 : Post-Displacement
Ti.
L1
Lri
T2
k22DF
Figure 6.8: Displaced system structure
where
T, - the i th tissue compartment
I	 - the delivery rate constant for compartment i
k21 - the efflux rate constant for compartment i
The volume of distribution of system 1 is given by,
VD1
i=1 2
and the volume of distribution of the second system is defined by,
n
v-'
and hence the following relation is obtained,
(6.20)
(6.21)
DF.	 (6.22)
Using the approximate change in Volume of Distribution, an index of occupancy
can be obtained. The occupancy represents the fraction of sites which are filled
by the exogenous dose of cold flumazenil. The occupancy index is calculated as,
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VD1 - VD2 = -
	
(6.23)0cc = VD1
Interpreted in a compartmental framework the system corresponds to a sum of
ri. single compartments with influx rates K1 and efflux rates k2. At the time of
displacement the system's characteristics change; the influx remains constant but
the efflux changes by a factor equal to DF. When DF > 1 the basis functions
possess a "kink" and allow for the description of a displaced system. Figure (6.9)
illustrates a set of basis functions with a displacement factor DF = 2.
Basis Functions
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Figure 6.9: Basis functions for displacement study
A golden ratio search [105] is employed to find the value of DF which minimises
the least sum of squares fit to the data. The approach optimises DF within the
range 1 DF 10. An example of a fit obtained to a particular data set is
shown in Figure (6.10). The data is integrated over time intervals of 50 seconds
to reduce the size of the basis function matrix without a significant effect on the
solution.
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Displaced Flumazenil Curve (5 micro gJKg @ 1560 secs)
Th	 500	 1000	 1500 . 20D0	 2500 3000 3500 4000time (secs)
Figure 6.10: Typical fit (-) to displaced head curve data (x)
Results
A cohort of 12 patients was considered with 8 patients each receiving a different
dose of cold flumazenil, {2.5, 5, 7, 10, 12.5, 15, 20, 3Otg/kg}, at 20-30 mins after
the injection of the radiotracer. Four studies with no displacement were used
to calculate a baseline value for the occupancy index (0cc = .039 ± .011(lsd)).
Figure (6.11) illustrates the occupancy indices obtained from the eight doses of
cold flumazenil. The index of occupancy is plotted against the normalised dose
illustrating a saturation effect. It is evident that not all the signal can be displaced
and this is because some of the signal represents non-specifically bound ligand.
6.5.2 Discussion
This chapter has presented two novel additions to spectral analysis. The first, a
theoretical consideration, is a proof which gives conditions under which a unique
solution is guaranteed. The second, an application, extends the original technique
of Cunningham and Jones [34] to take account of systems involving displacement
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Figure 6.11: Plot of dose against occupancy index for [11 C]flumazeuil displaced
with cold flumazenil
of the labelled compound. Another basis set with useful properties is tet, this
basis set allows for a different range of kinetic behaviour for our system response
which the traditional set of exponentials prohibits. It allows for impulse response
functions whose initial values are zero. The method of spectral analysis may also
be extended to consider the case of two input functions. In this case both the
inputs are convolved with a set of exponentials and then fitted to the data. The
scheme of this approach as might be applied to a system involving metabolites
is shown in Figure (6.12). This novel approach is applied to ' 1 [C]thymidine in
Chapter 9 to try and predict the parent and metabolite contributions to the tissue
signal.
+6.5 Extensions of Spectral Analysis	 133
Parent
0	 a, e - f31t
Tissue
Metabolites
0
Figure 6.12: Multiple input spectral analysis applied to a system with labelled
metabolites in plasma and tissue
Chapter 7
[11 C]Thymjdjne
7.1 Overview
In this chapter, observations of data derived from clinical [' 1 C]thymidine stud-
ies are presented. The behaviour of the tracer is investigated in tumours and
it is seen that some encouraging results are obtained. Metabolic breakdown of
[11 C]thymidine in plasma and tissue during the course of the study contributes to
the PET signal and as a result these metabolites must be defined to allow ade-
quate interpretation of the data. This is studied in detail in the two subsequent
Chapters.
7.2 Introduction
[i lciThyrnidine is currently under investigation as an in vivo marker of cell pro-
liferation in tumours [114] [115] [116] [117] [118]. It is proposed that the tracer
[11C] thymidine is taken up into proliferative tissues and incorporated into DNA,
providing a measure of DNA synthesis from which cell proliferation can be in-
ferred. To date the assessment of anti-cancer therapies rely on crude clinical
response markers. The ability to measure cell proliferation in vivo would pro-
vide clinicians with a more sensitive marker of response to therapy which may
134
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be achievable at a preclinical level. Thus allowing great individualisation of the
therapeutic regime. These measures would enable the monitoring of tumours with
respect to radiotherapy, anti-cancer drugs, etc.
7.3 Methods
Nine patients were scanned with [11 C]thymidine and an independent ex vivo mea-
sure of tumour proliferation was obtained. Each 1 hour thymidine scan consisted
of 30 dynamic frames and the frame durations are given in Table (7.1). Following
each of these thymidine scans, the tumour was removed and stained with a molec-
ular immunology borstal 1 antibody (MIB 1) to produce a histological measure
of cell proliferation [119] [120] [121]. In this case the MIB 1 index was expressed
as the number of labelled cells out of a total of 2000 tumour cells counted. The
MIB 1 values are shown in Table (7.2).
10 x 30
	
secs
5	 x 60	 secs
5	 x 120 secs
5	 x 180 secs
5	 x 300 secs
Table 7.1: Frame lengths for thymidine scans
'I'able 7.2: MIB 1 antibody staining results from nine patients scanned with
['C]thymidine
he 2-D dynamic data sets were reconstructed using filtered back-projection (Han-
t&ing filter: cut-off 0.5xNyquist frequency) and a measured attenuation correction
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Figure 7.1: Decay-corrected tumour time activity curves from the nine
[11 C ] thymidine scans
was applied. ROT's were drawn around tumour rims on an "add" image (0-60
ruins) from each of the [11 C]thymidine studies. These regions were then applied
to the dynamic data sets and tumour time activity curves obtained. The tumour
time activity curves were corrected for the decay of the isotope and are illustrated
in Figure (7.1).
7.4 Results and Discussion
The terminal half-life in tissue was calculated by fitting an exponential to the tail
of the tumour time activity curves (between 1800 and 3600 seconds), i.e.
TAC18o0_36o0(t) =	 ( 7.1)
from which,
log(2)	 (7.2)5
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where ti is the terminal half-life of label in the tissue. The terminal tissue half-life
2
was calculated for the nine patients and the results are tabulated in Table (7.3).
Study 3 tj. (secs)
p03059 1.23e-04 5.62e+03
p03206 8.38e-05 8.27e+03
p03494 2.24e-04 3.09e+03
p03726 1.70e-04 4.09e+03
p03737 7.73e-05 8.96e+03
p03766 9.59e-05 7.22e+03
p03847 1.17e-04 5.91e+03
p03898 1.58e-04 4.37e+03
p03946 1.55e-04 4.46e+03
Table 7.3: Terminal tissue half-life of label in tumour for the nine patients
If, as hypothesised, [' 1 C]thymidine is retained by proliferative tissues, then the
terminal tissue half-life of label may correlate with the degree of proliferation. By
plotting the terminal tissue half-life of the total tumour radioactivity, it becomes
apparent that the half-life of label in tissue is indeed correlated to the independent
measure of cell proliferation, as shown in Figure (7.2). The correlation coefficient,
0.754, was significant (p < 0.02 for n 9).
This result suggests increased retention of the label in highly proliferative tissues.
This may reflect either increased incorporation into DNA or slower turnover of
label due to higher intracellular concentrations of endogenous thymidine in highly
proliferative tissues. These results illustrate the potential of [ 11 C]thymidine as a
marker of cell proliferation. However, in the set of studies presented, only the
behaviour of total label in tissue was analysed. To obtain a more comprehen-
sive understanding of the mechanisms involved it is necessary to take account
of the contribution of labelled metabolites to the signal. The metabolism of
["C}thymidine, of which the major labelled metabolite produced is "CO 2 is con-
L0
rI)
F-
I
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MIB 1
Figure 7.2: Correlation between MIB 1 and terminal tissue half-life
sidered in Chapter 9. A series of bicarbonate studies was therefore proposed in
order to investigate the behaviour of carbon dioxide and enable clarification of
the [11 Cjthymidine signal. Before returning to modelling of [11 C]thymidine the
measurement and modelling of labelled carbon dioxide is dealt with in the next
chapter.
Chapter 8
Carbon Dioxide
8.1 Overview
11 CO 2 is the predominant metabolite for many "C labelled PET tracers [122].
["C]Thymidine is a typical example and is studied in detail in the next chap-
ter. To assess the contribution of labelled carbon dioxide in the thymidine scans,
a series of bicarbonate studies were proposed. These studies were to be per-
formed in conjunction with ["CJthymidine scans to enable characterisation of the
carbon dioxide system and subsequent "CO 2 correction of the thymidine data.
Extra information was obtained by monitoring the expired "CO 2 activity during
these studies. In this present chapter the analysis of the CO 2 data in both the
expired air and blood is described along with the calculation of tissue impulse
response filnctions. In this chapter refers to either in expired air or
"CO 2 /H"CO in blood (bicarbonate equilibrates rapidly with CO 2 in blood, see
chemical reaction scheme (8.1)).
112 0 + CO2 H + HCO	 (8.1)
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8.2 Methods
8.2.1 Monitoring of Exhaled Activity
A sensitive monitoring system which allows the continuous monitoring of the
levels of expired CO 2 and CO 2 during a PET scan was developed in response to
problems identified with the tracer [ 11 C]thymidine (Ranicar et aL, in preparation).
The expired air is sampled via a pair of soft plastic nasal prongs which are inserted
into the nostrils of the patient prior to scanning. As a result a proportion of the
expired air was drawn through a /+ plastic detection chamber to monitor labelled
11 CO2 and subsequently through a capnograph to monitor the stable CO 2 . Both
time courses are sampled at 10 Hz providing a good characterisation of each
breath.
8.2.2 Bicarbonate Scans
The data analysed here were taken from an ongoing programme of bicarbonate
studies. ' 1 CO 2 was injected intravenously as ["C]bicarbonate solution over a 30
second period. The time course of CO 2 in the subject was monitored in expired
air, blood and tissues of interest for the duration of the scan (1 hour). Tissue data
were collected according to the protocol of frame lengths given in Table (8.1). A
high temporal sampling rate was used initially to characterise the delivery and
distribution stages, followed by longer frames to characterise the tracer uptake.
8.3 Results
8.3.1 Exhaled Activity as a Measure of Blood and Plasma
Activity
Typical examples of the time courses of exhaled 11 CO 2 and CO 2 are shown in
Figures (8.1) and (8.2), respectively. These data were collected following intra-
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1 x 30	 secs
6 x 5	 secs
6 x 10	 secs
6 x 20	 secs
6 x 30	 secs
3 x 300 secs
4 x 600 secs
Table 8.1: Frame lengths for bicarbonate scans
venous administration of [11 C]thymidine (see Chapter 9). 11 CO 2 was detected in
the breath almost immediately, reflecting the rapid whole body catabolism of the
parent tracer. Inspection of this type of data suggested that the "envelope" may
provide a suitable description and measure of the underlying time course of 11CO2
in the blood.
timc (secs)
Figure 8.1: Exhaled "CO 2 data
A magnified version of the exhaled ' 1 CO 2 data is shown in Figure(8.3). The
respiratory oscillations in the raw data are clearly defined. The raw data were
characterised by examining it's power spectral density, as calculated by the Welch
method [123]. The corresponding power spectral density of the exhaled "CO2
DO
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lime (secs)
Figure 8.2: Exhaled CO 2 data
data is shown in Figure (8.4). A power spectrum defines the power of the signal
at each frequency. The method provides a more robust spectral estimate than
a Fourier transform of the autocorrelation function by averaging across adjacent
records. The Welch method has the advantage that the variance of the power
spectral density estimate tends to zero with increasing signal length. The process
may be summarised as follows;
• Separate the sequence into sections of length 256.
Multiply each section by the Hanning window (window length 256).
• Take Fourier transform of the sections.
• Accumulate results for all sections and then normalise.
The power spectrum yields two important pieces of information. Firstly, in the
example shown it can be seen that the power of the signal decreases above 2 Hz,
and secondly, the maximum energy of the signal occurs at a frequency of 0.186
Hz. This suggested that the raw data could be smoothed with a low pass filter
with a cut-off frequency of 2 Hz. A 4th order Butterworth filter was applied and
V
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Figure 8.3: Exhaled "CO 2 data (+) together with low pass filtered signal (-)
the smoothed time course is shown as a solid line in Figure (8.3). This allows the
peak value of each breath to be used as a more robust measure of the envelope.
Figure 8.4: Power spectral density of labelled CO 2 data
The power spectral density may also be used to obtain the frequency for which
the signal has maximal energy. This corresponds to the average respiration rate
of the subject. The maximum energy of the signal has a frequency of 0.186 Hz
which corresponds to a respiratory cycle of 5.40 seconds, see Figure (8.4). Having
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determined the average period of the respiratory cycle, (rc), this length was used
as a window with which to search the filtered ' 1 CO2 data for maximum. Once
a maximum has been found at t the next maximum is obtained in the interval
[t + , t + 2]. This procedure may then be carried out for the whole curve to yield
a peak exhaled ' 1 CO 2 curve, see Figure (8.5). The same procedure of filtering and
000
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time (sees)
Figure 8.5: Peak exhaled 11 CO 2 data
peak finding was applied to the stable CO 2 to produce a peak exhaled CO 2 curve,
Figure (8.6). A point by point ratio of the two curves was then obtained. The
stable CO 2 curve was used to normalise for varying breath volumes, see example
in Figure (8.7), and by inspection this is a smoother curve than the labelled CO2
(see example in Figure (8.5)).
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Figure 8.6: Peak exhaled CO 2 data
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Figure 8.7: Normalised exhaled ' 1 CO 2 data
Blood CO 2 Time Course
The next stage was to establish a relationship between the normalised exhaled
11 CO 2
 (e.g. Figure (8.7)) and the time course of ' 1 CO 2 activity in blood. Ex-
periments were therefore carried out in which the subjects received 11 CO 2 alone,
as an intravenous injection of 11 C bicarbonate. These experiments were carried
out in conjunction with [11 C]thymidine scans as described in the next chapter.
time(secs) time(secs)
0
00
0
0
30 00
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Bicarbonate solution was intravenously injected over a 30 sec period and the time
course of 11 CO 2 was continuously monitored in breath, as described previously.
Total radioactivity was also assayed on-line in blood, and discrete blood samples
were assayed for the fraction of '1 CO 2 . The results for a typical scan are shown
in Table (8.2).
Time (secs) % HCO
0	 100
100	 99.19
309	 97.81
640	 97.30
1817	 95.68
3614	 92.32
4708	 89.96
Table 8.2: Fraction of blood activity due to HCO for p4161 bicarbonate study
Figure 8.8: Blood activity and exhaled activity from bicarbonate scan (p4161)
The discrete measurements of the fraction of 11 CO 2 in the blood allowed the
creation of an 11 CO 2 blood input function. A linear interpolation of the discrete
measurements was employed to fit a gradual decrease in the percentage of 11CO2
0It)
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(to approximately 90% at 1 hour). The ' 1 CO 2 blood and ' 1 CO 2 exhaled curves
were matched allowing for a time delay (*.# 30 secs) between them and a simple
scaling factor based on the total collected counts. The result for one example is
shown in Figure (8.8). This shows that the two measurements are indeed very
similar and by plotting these two measures against each other the relationship is
more clearly defined, as shown in Figure (8.9). The two measures are very well
matched except for small differences around the initial part of the curves. These
differences may be due to a small amount of dispersion of the two measures.
Blood Activity
Figure 8.9: Correspondence plot of blood 11 CO 2 activity against exhaled '1CO2
activity (Line of identity is also shown)
Plasma CO 2 Time Course
Figure (8.10) shows that the relationship between total label in plasma and that
in whole blood for the 11 CO 2 scans was linear. Hence, a plasma 11 CO 2 input
function was created by multiplying the blood 11 CO 2 time course by a factor of
1.62. Analysis of this equilibration in terms of a partition model and an average
haematocrit of 0.4 ,as described in Chapter 5, suggests that 96% of the label was
present in the plasma.
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Figure 8.10: Plot of "CO 2 activity in 1 ml of whole blood versus "CO 2 activity
in imi of plasma for four studies (Different symbols represent separate scans)
8.3.2 Tissue Kinetics of 11CO2
The second purpose of the "C bicarbonate scans was to determine the unit impulse
response functions of various tissues to the "CO 2 in plasma, with a view to
subsequent correction of tissue data for the presence of "CO 2 in plasma, deriving
from whole body metabolism of parent tracers such as ["C]thymidine as described
in chapter 9. Analysis of the plasma to tissue dynamics of CO 2 was examined
using spectral analysis. An impulse response function IRFo2 (t) was obtained
such that,
Turnourco2(t) IRFc02 (t) ® Plasmaco2 (t)	 (8.2)
The CO 2 plasma input function was convolved with a series of exponentials and
these functions, considered as basis functions, were subsequently fitted to the
tissue time activity curves as described in Chapter 6. A fit obtained to a typical
tumour time activity curve is illustrated in Figure (8.11). Results obtained for
0DO
8.4 Summary	 149
Fit To Tissue CO2 Time Course
Time (sees)
Figure 8.11: Spectral analysis fit (-) to tumour time activity curve (o) for bicar-
bonate data (p416l)
the four bicarbonate scans are given in Table (8.3) and the impulse responses
are shown in Figure (8.12). Analysis of the spectra obtained revealed three key
kinetics components. A blood volume component, a flow component and a small
amount of trapping. The impulse responses returned for the tumours in either
study show different behaviour. These initial results indicate the variability of the
system response in tumour which may reflect differing pH of the tumours [124]
[125].
8.4 Summary
The measured exhaled "CO 2 can be transformed to give a continuous measure
of "CO 2 in blood or plasma. The application of the tumour impulse response
functions will be discussed in the next chapter.
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Figure 8.12: CO 2 impulse responses in tumours obtained from spectral analysis
of bicarbonate data (for all four studies)
Study no. /(s') a(s')
p4060 l.Ole-3 4.53e-5
2.36e-3 4.46e-5
1.67e-2 5.85e-4
___________ 3.94e-1 2.98e-2
p4161
	
	 5.75e-4 1.09e-5
3.97e-3 4.56e-4
___________ 1.22e-2 2.51e-3
p4132 5.75e-4 1.31e-5
2.65e-3 3.26e-4
1.09e-2 1.79e-3
___________ 1.00
	 1.08e-1
p4213 5.75e-4 1.13e-5
4.75e-3 3.14e-4
1.76e-2 4.44e-3
3.12e-2 2.31e-4
1.00	 7.92e-2
Table 8.3: Spectral analysis of tumour data from four bicarbonate scans
Chapter 9
Modelling of [ 11 C]Thymidine in
Plasma and in Tissue
9.1 Overview
This chapter considers [2-"C]thymidine as a PET tracer, its degradation pathway,
modelling of plasma metabolites, and methods for analysis of the time course of
label in tissues of interest. CO 2 is identified as the major metabolite in plasma
and a method for correcting the tissue signal for 11 CO 2 deriving from plasma is
presented. This method involves a 11 CO 2/[' 1 C]thymidine two scan protocol. A
dual input spectral analysis was also considered.
9.2 Introduction
The principal problem inherent in the use of radiolabelled thymidine as a PET
tracer in tumour studies is the contamination of signal due to labelled metabolites,
not only in plasma but also in the tissues in the field of view. This contrasts
with the radiolabelled ligands discussed previously, such as diprenorphine and
fiumazenil, whose metabolites would not be expected to cross the blood brain
barrier and the tissue signal is not contaminated by metabolites [91] [92].
[3H]Thymidine has been used in vitro and in animal work [126], [127] to investigate
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tumour proliferation. On administration thymidine is either directly incorporated
into DNA or rapidly metabolised. However initial studies using tritiated thymidine
in mouse, rat and dog tumour models demonstrated a high tumour to tissue uptake
ratio with prolonged retention in tumour [126] [128]. In mouse tumour models a
significant correlation has been shown between [ 3H]thymidine uptake and tumour
grade [126]. Absolute quantification of thymidine incorporation into DNA might
not be possible simply by using a plasma born tracer, because of endogenous tissue
synthesis of thymidine and reutilisation of thymidine from dying cells. However
it may prove of great value as a quantitative index of tumour status as suggested
by the results presented in Chapter 7.
9.2.1 Labelling of Thymidine
Thymidine has been labelled with 11 C in two different ring positions, [2-11C]
[129] and [methyl- 11C] [130]. With thymidine labelled in the C-2, position the
label follows a catenary metabolic path through thymine, dihydrothymine, N-
Carbamoylisobutyrate (intermediary metabolites) before the label is lost in the
form of CO 2 [122] [131], as shown in Figure (9.1). Advantages gained in labelling
thymidine in the C-2 position are the presence of fewer labelled metabolites and a
larger proportion of labelled DNA in tumour [114]. Further advantages include the
major labelled metabolic component being 11 CO 2 ; extra 11 CO 2 measurements can
be obtained via the measurement of expired labelled "CO 2 , as has been described
in the previous chapter. When [ 11 C]thymidine is labelled in the methyl position
more labelled metabolites are produced creating a more complex system and the
proportion of labelled DNA in tumour is significantly smaller [114]. Vander Borght
et al. [132] have demonstrated the advantages of using [2- 14 C]thymidine as a po-
tential index for liver regeneration, they also concluded that the 2-C label was
preferable (no accumulation of labelled metabolites) to the methyl label (labelled
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Figure 9.1: Catenary metabolism of [2-'1C]thymidine
metabolites in tissue). For thymidine to become a useful PET tracer it is
sary to quantify the behaviour of its metabolites in both plasma and tissue. The
studies analysed in this thesis consider thymidine labelled in the 2-C position.
9.3 Modelling
11 CO 2 is the major labelled metabolite of ["C]thymidine and an accurate descrip-
tion of its time course in tissue and plasma is essential for the quantification of the
behaviour of thymidine in tumour and tissue. The purpose of this chapter is to
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describe models which attempt to take into account the contribution of labelled
rnetabolites to the plasma and tissue signals following intravenous injection of
['1 C]thymidine. The availability of discrete measurements of the metabolites in
plasma allows for correction of the plasma time course. In tissue the correction
is more complicated as no chemical resolution is possible. Methods for correction
must rely on the actual kinetics of thymidine and its metabolites being identifiable
from the total label time course, or the performance of additional experiments.
An approach to the modelling of [ 11 C]thymidine kinetics has been presented by
Mankoff [133] which extends the method of graphical (or Patlak) analysis to con-
sider systems containing labelled metabolites. This method applies if the tracer
[11 C]thymidine is irreversibly trapped in tissue but the labelled metabolites are
not.
9.4 Methods
Four [11 C]thymidine scans (paired with [11 C]bicarbonate scans) were performed.
The [11 C]thymidine scans were initiated 10-20 minutes after the end of the bicar-
bonate scans (described in Chapter 8). The tracer was injected intravenously as a
smooth bolus over 30 seconds. Dynamic data sets were acquired and reconstructed
as described previously (section 7.3). A simultaneous measure of the expired ra-
dioactive attd stable CO 2 was collected together with a continuous measure of the
whole blood activity. Discrete samples of blood were removed during the scan for
three purposes; namely calibration, calculation of the fraction of label in the blood
due to HCO (Blood samples were divided into two. The first sample was added
to NaOH to trap the 11 CO 2 and this test tube was rapidly capped to avoid any loss
of 11 CO 2 . The second sample was added to isopropanol followed by HC1 to release
' 1 CO 2 . Nitrogen gas was then bubbled through each sample to help this process
before both samples were assayed for radioactivity [122] [131]) and calculation of
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the fraction of label due to thymidine after the removal of 11 CO 2 in plasma (Blood
was centrifuged and a plasma sample obtained was added to methanol to precip-
itate proteins. The thymidine and metabolite components were then obtained in
the methanol which was injected into the HPLC system for analysis).
0.5 Results
9.5.1 Plasma Time Courses
The time course of radioactivity in blood was segmented to give time courses of
[' 1 C]thymidine, ["Cjintermediary metabolites and 11 CO 2 in plasma. A diagram-
rxiatic representation of this process is shown in Figure (9.2). A plasma '1CO2
time course was generated using the exhaled 11 CO 2 activity, the continuous mea-
sure of whole blood activity and discrete measures of the fraction of total label in
blood as HCO (see section 8.3.1). A typical example of an 11 CO 2 time course
and fit to the discrete blood measurements is illustrated in Figure (9.3). This
measure was scaled by a factor of 1.62 to give a plasma 11 CO 2 time course (see
section 8.3.1). The whole blood time course was converted into a plasma time
course using a linear interpolation and extrapolation of the plasma to blood ratio.
The 11 CO 2 plasma time course was subtracted from this measure to leave just
labelled thymidine and intermediary metabolites. The remaining segmentation of
the plasmacurve was achieved by fitting a functional form to the measured frac-
tion of thymidine in plasma (CO 2 had been removed from the plasma samples).
The functional form used was,
Thymidine Fraction(t) =	
- _____	
(9.1)
I'	 (t-6)+c
	
-
This function was fitted to the metabolite data and a typical fit can be seen in
Figure (9.4). This function was used as it extrapolates the thymidine fraction to
zero and also fitted better than an exponential approach to a constant. This gave
CO2
Plasma
Time
Course
Plasma
Time
Course
x
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Figure 9.2: Scheme of plasma input function generation
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Figure 9.3: Calibration of exhaled 11 CO 2 using direct blood assays
Fit to Thymidine Fraction
time (sees)
Figure 9.4: Fit to thymidine fraction in plasma (excluding CO 2 ) using functional
form
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Figure 9.5: Distribution of label in plasma (p4161)
three plasma input functions; [ 11 C]thymidine, [11 C]intermediary metabolites and
11 CO 2 . Typical time courses for these plasma time courses are shown in Figure
(9.5). It is obvious from these data that thymidine disappears very quickly from
the plasma. After approximately 15 minutes the thymidine level in plasma is so
small it is difficult to measure.
Initial investigations were carried out in an attempt to derive a compartmental
relationship between ["C]thymidine, 11 CO 2 and ['C]intermediary metabolites,
the latter being considered as a single compartment. This was performed with a
view to obtaining a function describing the [' 1 C]thymidine and ' 1 CO 2 fractions
in terms of the total label time course. Unfortunately, it was found that models
describing such a relationship were numerically unidentifiable with a high degree of
parameterisation required. However it is interesting to consider the relationship
between labelled [' 1 C]thymidine and the major metabolite, labelled "CO 2 , in
plasma.
Do
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9.5.2 [ 11 C]Thymidine and 11 CO 2 in Plasma
To investigate the metabolism of ["C]thymidine further, the plasma "CO 2 con-
centration was examined as a function of the plasma [C]thymidine concentration
using the method of spectral analysis. The "CO 2 plasma time course was fitted
as a linear combination of a set of basis functions, which comprised different ex-
ponentials convolved with the plasma thymidine input function. A typical fit
is shown in Figure (9.6), and the components chosen by the NNLS method are
presented in Table (9.1).
time(secs)
Figure 9.6: Spectral analysis fit (-) to exhaled 1 'CO 2 data (0) (p4161)
p4161 f3(s') [o(s')
Exhaled 6.08e-04 9.22e-04
"CO2 2.21e-03 1.98e-03
1.80e-02 2.24e-03
_________ 1.00	 9.43e-03
Table 9.1: Spectral analysis of exhaled "CO 2 as a function of plasma thymidine
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The presence of fast components in the spectrum indicates that the metabolism
of ["C]thymidine to " CO 2 is very rapid and this is reflected by the concentration
time course of	 in plasma.
Summary
A method has been presented for the correction of the contribution of labelled
metabolites to the plasma signal. It is now necessary to consider techniques for
similarly correcting the tissue signal.
9.5.3 Correction for [' 1 C]Carbon Dioxide in Tissue
The problem of identifying the tissue kinetics of [' 1 C]thymidine is complicated by
the presence of the confounding metabolite signal in the tissue of interest. Res-
olution of the tissue signal requires kinetic models or additional experiments to
be performed. To obtain additional information on the behaviour of CO 2 in tis-
sue a set of "CO 2 scans in conjunction with [' 1 C]thymidine scans was proposed.
The scheme is shown in Figure (9.7). The bicarbonate scans allowed for plasma
to tissue dynamics of CO 2 to be identified. This information was then used in
conjunction with the ["Cthymidine scan to remove the contribution of "CO2
in tissue originating from the plasma. The carry over of radioactivity from the
["C]bicarbonate scans to the ["C]thymdine scans was monitored using a back-
ground frame and was negligible.
Removal of CO 2 Tissue Contribution using Paired Scans
The four bicarbonate scans were analysed with spectral analysis, as described in
the previous chapter, creating impulse response functions (IRFc02 (L)) for CO 2 in
the tumours (see Figure (8.12)).
Plasma input functions were obtained for the ["C]tbymidine scans using the meth -
ods presented in section (9.5.1). The 11 CO 2 plasma input function was convolved
Bicarbonate Scan
Plasma	 Tissue
I co2I<	 Co2 I
/
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Figure 9.7: Dual scan method enabling correction of CO 2 in tissue
with the CO 2 impulse response for the system, producing the component of 11Q2
in tissue due to the exchange of 1 CO 2 between plasma and tissue. This CO2
component may then be removed from the total label time course by subtraction,
i.e.
Turnourco2 correcjed(t) = TumourLabel (t) - IRFc02 (t) 0 Plasrnaco2 (t) (9.2)
The time courses of total label in tumour and the appropriate 11 CO 2 corrections
for the four studies are shown in Figures (9.8 - 9.11).
It is evident that the contribution of carbon dioxide to the signal is significant.
The percentage contribution of carbon dioxide at 1 hour is given in Table (9.2).
These results are consistent with work performed by Shields et al. in animals who
found that 80% of label in animal tumours one hour post injection was accounted
for by labelled DNA [114]. They also found that methyl labelled thymidine gave
only 40% as labelled DNA at one hour, again demonstrating the advantages of
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Figure 9.11: Correction of tumour time course for the presence of ' 1 CO2 (P4213)
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Study % CO 2 at 60 mins
p4060	 30.3k
p4161	 14.4
p4132	 28.7
n4213	 37.2
Table 9.2: Contribution of carbon dioxide in tumour at 60 minutes (extrapo1ated,
see Figure (8.8))
using the [2-' 1 C] label. Under the assumption that the animal results can be ex-
trapolated to human studies it would suggest that there is little or no contribution
from the intermediary metabolites in tumour.
Initial results suggest that a standard correction for carbon dioxide may be difficult
to apply due to the variability in impulse responses. However, the dynamics of
carbon dioxide are very fast and a model could approximate the contribution
simply as a plasma or blood volume term in any modelling procedure.
9.5.4 Dual Input Spectral Analysis
To assess whether the kinetics of [ 11 C]thymidine and 11 CO 2 could be distinguished
implicitly from the tumour time activity curves, the method of dual spectral
analysis was implemented and applied. This technique is an extension of the
standard spectral analysis technique involving just a single input function (see
Chapter 6). The problem is considered such that the tissue constitutes labelled
thymidine and carbon dioxide. Plasma input functions were identified for these
two compounds as described previously. The tumour time activity curves were
then fitted to a composite function of possible thymidine and carbon dioxide
behaviour. This is described mathematically by,
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100	 100
PETtumour (t) = Plasmathymidine (t)® aje1t+PlasrnacQ2(t)® 7•6--/31t (9.3)
1=1	 j=1
subject to the non-negativity constraint aj , 'i ^ 0.'
This equation was applied to the tumour time activity curves utilising the NNLS
algorithm described in Chapter 6. This was applied to all four studies and the pre-
dicted components (Spectral analysis approach) are compared with the measured
components (two scan approach) in Figures (9.12 - 9.15).
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Figure 9.12: Prediction of carbon dioxide contribution in tumour using spectral
analysis (p4060)
Unfortunately the spectral analysis fails to characterise the different kinetics.
However, the shapes of the curves are correct and if further constraints could
be applied it might be possible to predict the curves (i.e. if the ' 1 CO 2 fraction in
tissue was known at 60 mins).
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Figure 9.13: Prediction of carbon dioxide contribution in tumour using spectral
analysis (p4161)
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Figure 9.14: Prediction of carbon dioxide contribution in tumour using spectral
analysis (p4132)
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Figure 9.15: Prediction of Carbon dioxide Contribution in tumour using spectral
analysis (p4213)
Parametric Images
The correction of [11 Cjthymidine scans using a [11 Cjbicarbonate scan and equation
(9.2) may be applied at a single "pixel" level. This method was applied to create a
' 1 CO 2-corrected dynamic data set. Spectral analysis was then applied to both the
uncorrected and corrected data sets using a [' 1 C]thymidine plasma input function
and the impulse response functions were derived at 60 minutes. These images
are representative of the retention of the total uncorrected and corrected tracer
signal. A transaxial slice through the abdomen is shown in Figure (9.16). It is
clear from the images that the 11 CO 2 correction removes a large part of the diffuse
' 1 CO 2 signal thus enabling the production of more accurate functional images of
thymidine retention.
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Figure 9.16: Thymidine impulse response functions imaged at 60 minutes with
and without correction for the contribution of carbon dioxide in tissue
9.6 Discussion
The first clinical application of [ 11 C]thymidine uptake in tumours using PET was
described by Martiat et al. [134] using thymidine labelled in the methyl position.
In this work a relatively simple compartmental model was employed and it was
argued that the signal due to labelled metabolites was unimportant. They showed
a correlation between the uptake of [' 1 C]thymidine in lymphoma and histological
grade. The advantages of thymidine labelled in the 2-C position was first proposed
by Vander Borght [129] and its application to PET was studied further by Shields
[114] who drew attention to the need to take the contribution of metabolites
into account in any subsequent analysis. A plausible compartmental model for
the analysis of the behaviour of [ 11 C]thymidine and its labelled metabolites was
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also proposed by Shields [114]. However, as the author commented the model
is over-parameterised and numerically unidentifiable from the PET data. More
recently Mankoff et al. [133] from the same group have suggested a graphical
Patlak approach. The technique assumes that none of the metabolites involve an
irreversible step, such an assumption would be invalidated by any fixation of CO2.
Although Mankoff et al. do consider the case where there is a "small" amount of
metabolite trapping, they agree that it is difficult to mathematically separate the
contribution of [11 C]thymidine and its labelled metabolites in this case. In this
thesis I have demonstrated that the determination of the relative contributions of
["C]thymidine and metabolite components, simply from the total label in tissue,
is non trivial with the application of dual input spectral analysis. Both this
technique and that of Mankoff et al. stem from basically the same model and are
therefore likely to suffer from similar inherent problems.
The approach used in the present work has been to address the metabolite prob-
lem directly, and to conduct an additional scan aimed at characterising the be-
haviour of the principal labelled metabolite, namely 11 CO 2 . The advantages of
this approach are simply that it allows for the removal of 11 CO 2 from the tissue
signal, enabling subsequent modelling techniques to be simplified. A disadvantage
arises from the need for an additional scan. For example, it may also be neces-
sary in some cases to combine the thymidine scans with an HO blood flow scan
to investigate delivery. However, the consecutive acquisition of all three studies
would rarely be feasible. The work presented in this chapter has been based on
four paired scans. These preliminary data are insufficient to examine whether
population data could be used to correct for the "CO 2 contribution in tissue in
the general case. On the basis of the present analyses further paired scans are
therefore being carried out in the Unit.
The present analyses were carried out as part of a programme investigating the
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potential use of [11 C]thymidine in PET as a marker of tumour cell proliferation. In
this context the present work establishes an experimental approach to the removal
of the confounding signal from the major metabolite. The next steps will involve
the investigation of the corrected signal to see if it provides a more robust index of
cell proliferation. Clearly this presents a difficult exercise in validation - a possible
approach however is suggested by the results presented in Chapter 7 on MIB 1.
With the benefit of hind sight it may be profitable to repeat these studies coupled
with the two scan approach presented here.
Chapter 10
Conclusions and Future Work
10.1 Conclusions
This thesis has considered three main themes; identifiability analysis, tracer ki-
netic modelling and contamination of the data by labelled metabolites. After
an introduction to PET, modelling and identifiability analysis (Chapters 2 and
3) the thesis considered unidentfiable systems in Chapter 4. A new method has
been presented which allows for the reparameterisation of unidentifiable systems.
The method was based on the Taylor series approach to identifiability analysis
and enables the original unidentifiable system to be reduced to a locally identi-
fiable system. Furthermore this reparameterisation may be globally identifiable.
Theorems have been presented, firstly to give conditions for the existence of a
reparameterisation of an unidentifiable model and secondly to dictate how a repa-
rameterisation must be constructed. This reparameterisation method was then
applied to a metabolism model in Chapter 5 which considered methods for the
correction of the plasma input function due to labelled metabolites. Chapter 5 has
considered using compartmental models for the description of metabolite foria-
tion and two models were presented for the metabolism of ["C]diprenorphine and
[11 C}flumazenil. A partition coefficient model was applied to ["C]fiumazenil blood
data which allowed for the creation of metabolite data solely from the distribution
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of label between plasma and red cells. These findings spawned a proposal for a
future blood sampling protocol involving fewer metabolite samples. This would
enable metabolite correction of the plasma curve using the compartmental and
partition coefficient models.
Chapter 6 considered a tracer kinetic modelling technique (spectral analysis) with
reference to the problem of the uniqueness of the solution. A Theorem was pre-
sented which gives a sufficient condition for a unique solution to the spectral
analysis problem. This condition is normally satisfied in practice. The method of
spectral analysis was extended to consider systems involving displacement of the
tracer signal. This method was applied to a set of head displacement data, from
a whole body counter, utilising a novel set of basis functions. This allowed for the
change in occupancy to be inferred.
Chapter 7 investigated [' 1 C]thymidine, a possible tracer for the (in-vivo) mea-
sure of tumour cell proliferation. PET derived indices of tumour cell proliferation
were found to correlate with an ex-vivo histological measure. The PET tracer
['1C] thymidine suffers from the metabolism of the injected compound, the major
rnetabolite being "CO 2 . Therefore dual experiments were proposed and per-
formed using both 11 CO 2 and [11 C]thymidine. This novel dual scan approach al-
lowed for the removal of the contaminating 11 CO 2 contribution to the tissue data.
This correction was performed using spectral analysis to characterise the carbon
dioxide tissue dynamics and then convolution with the carbon dioxide plasma
time course to establish the contribution to the tissue signal. The "CO 2 plasma
time course was obtained using a novel breath sampling and analytical technique
for characterising expired radioactivity. The applicability of a dual input spectral
analysis method was investigated as a kinetic modelling technique to distinguish
between the ["C]thymidine and "CO 2 signals in tissue. Unfortunately this failed
to resolve the two time courses.
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10.2 Future Work
It is anticipated that the following work will be carried out in the future.
A revision of the [11 C]flumazenil protocol will be implemented as proposed at
the end of Chapter 5. This will utilise the partition coefficient model to enable
accurate estimation of metabolite data at late time points.
The method of spectral analysis for displacement studies will be extended to
consider data on a tomographic scale. The technique will necessitate statisti-
cal considerations at this resolution, and a proposed method involving an F-test
of displaced and undisplaced spectral methods will be investigated to determine
whether individual pixels contain a displaced signal.
[ C] Thymidine experiments will be carried out as proposed at the end of Chapter
9, further examining the possibility of a standard ' 1 CO 2 correction. 11 CO 2 correc-
tj0
 of the [11 Cjthymidine data will allow for a more comprehensive investigation of
["C] thymidine kinetics. Experiments involving ["C] thymidine, [11 C]bicarbonate
nd MIB 1 measures are being planned to validate the use of ["C]thymidine as
in vivo marker of cell proliferation.
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Appendix A
Jacobian Coefficients
A.1 Example 2 : Nonlinear Saturable Ligand
Binding Model
The jacobian matrix is defined by,
G11 G12 G13 C14 G15 C16
C21 C22 G23 C24 C25 C26
C (a) = G31 G32 C33 C34 G35 C36	 (A.1)
C41 C42 C43 C44 C45 G46
G51 C52 C53 G54 C55 C56
The following output was generated using MATHEMATICA, a mod- em symbolic
manipulation package.
G11=1
C12 =0
C13 = 0
193
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C14 0
C15 = 0
C16 0
C21 = —k2
022 = - 1(1
023=0
024=0
025=0
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G26=:O
C31 = k2 + k2konBmax
Vr
K- konBma
G32 = 2K1 k2
 +
Vr
K1
 k2Bmax
G33 =
Vr
- K1lC2komBmav
G34--	
V2r
K k21v0
G35 -
Vr
G36=O
k2 (k2 2 17r 2 + 2Ki kon 2 Bmax + 2k2 kon Vr Bma + kon 2 Bmax 2 + konVrBmaxkoff
G41 =—
G42 = -
K1 (31 2 2 Vr 2
 + Ki kon 2 Bmax + 4k2 kom Vr Bmax +L 2 Bmax 2 + konVrBrnaxkof I
Vr
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Ki k2 Bmax (2K1 k0 + 2k2Vr + 2kon Bmar + Vrkoff)C43 = -
	 V2
Ki k2 kon Bma (2K1 k0 + 2k2 Vr + 2kon Bmax + Vrkoff)C44 =
	 v
K1 k2 k0 (K1 k0
 + 2k2 Vr + 2kon Bmax + Vrkoff)C45 = -
	 V2r
K1 k2konBmaxG46 - _______________
Vr
C51 =
k2
 (k2 3Vr 3 + 3K1 2	+ 8K1 k2 k0 2 VrBmax + 3k2 2 kon Vr 2Bmacb0fl -'-'max
Vr
+8Ki kon 3Bmax 2 + 3k k 2VB 2 + kon3B7nax3
 + 4Ki kon 2 Vr Bmax kojj + 2k2konVr 2 Bma2 on r max
V3r
+2/02T7 D 2 k0ff + konVr2Bmaxkoff2)'r -'-'max
V 3r
i	 + K1 2 kon 3Bmax + 8K1 k2 kon 2 Vr Bmax + 9k2 2 konVr 2 -'--'max
G52 =
	 V3r
+4Ki kon3 Bmax 2 + 6k2 kon 2 Vr Bmax 2 + kon3 Bmax3 + 2Kl kon2 VrBmaxkoff + 4k2konVr2B,
+2kon 2 Vr Bma 2 koff +1C v 2	 kf)on r -'--'max o
V 3r
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G53 =
Ki k2 Bma (3Ki 2 kon 2 + 8K1 1c2 k0 V + 3k2 2 V 2 + l2Ki kon 2 Brna + 6k2konVrBmax
VT
+3kon 2Bmax 2 + 4K1 k0 Vk0 + 2k2 V 2 k0ff + 4kon Vr Bmax koff + V2k0ff2
Kik2konBrn (3K12k02 + 8K1 k2 k0 V + 3k2 2 V 2 + 12K1kon2B.jmcx
G54 = -
	 V4
+6k2 konVrBmax + 3kom 2 Bmav 2 + 4Klk0flV1c0f I + 2k2 V 2 k0ff + 4kon Vr Bmax koff + V2k0
TI4VT
K1 k2 k0 (K1 2 k0 2 + 4K1 k2k0 V + 3k2 2 V 2 + 8Ki kon 2 Bmar + 6k2konVrBmax
C55	
V3
+3korj 2Bmax 2 + 2Kl kon VT koff + 2k2 VT 2 k0ff + 4kon Vr Bmax koff + V2k0ff
T/ 3VT
- 2Ki k2 kon Bma ( K1 k0 + k2V + konBmax + Vkoff)C56 -
	 T/2
VT
A.2 Example 3 : Reference Region Model
The jacobian matrix is defined by,
C11
G21
C(a)= C31
G41
C51
G12 G13
C22 G23
G32 C33
G42 G43
C52 G5
G14 G15 G16
G24 C25 C26
G34 C35 G36
C44 C45 C46
G54 C55 G56
(A.2)
The following output was generated using MATHEMATICA,
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1
G11= k-
G13=O
K1
G15 =
115
C16 = 0
—k2 + k6
C21 
= K5
K1
C22 = --i:;-
115
C23 = 0
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G24=O
K1 (k2 - k6)
=	 K52
K1
C26 =
115
k2 (k2 + k3 - k6)
C31
K5
K1 (2k2 + k3 - k6)C32 =
K5
K1 k2
G33 
= K5
G34=O
K1 k2 (k2 + k3 - k6)
G35 =-
115
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K1 k2
036 
= - K5
k2 (k22 + 2k2 k3 + k3 2 + k3k4 - k2 k6 - k3k6)
G41 = -
K5
i (2 2 + 4k2 k3
 + k3 2 + k3 k4 - 2/c2 k6 - k3k6)
042 = -
K5
043 
= K1 k2 (2k2 + 2k3 + k4 - k6)
K5
K1k2k3
044=— K5
- K1 k2 (k22 + 2k2 k3 + k3 2 + k3k4 - k2 k6 - k3k6
045 -
115
K1 k2 (Ic2
 + k3)
G46 -
	 K5
Ic2 (1c23
 + 3k2 2 1c3
 + 3k2 k3 2 + Ic33 + 2/v2 k3 1c4 + 2k32k4 + 1c3k4 2 - Ic2 Ic - 2/c2k3k6
G5j =
.L 5
—k3 2 k6 - Ic3 Ic4 Ic6)
K5
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i ('i 2 + 9k2 2 k3 + 6k2 k32
 + k33 + 4k2 k3 k4 + 2k3 2 k4 + k3 k42 - 3k2 2 k6 - 4k2k3k6
G52 
= 115
—k32 k6 - k3k4k6)
K5
K1 k2 (3k2 2 + 6k2 k3 + 3k32 + 2k2 k4 + 4k3 k4 + k42 2k2 k6 - 2k3 k6 - k4k6
G53 =
K5
= K1 k2 k3 (2k2 + 2k3 + 2k4 - k6)
K5
K1 k2 (k2 3 + 3k2 2 k3 + 3k2 k3 2 + k33 + 2k2 k3 k4 + 2k32 k4 + k3 k42 - k2 2 k6 - 2k2k3k6
G55 =-
115
—k32 k6
 - k3k4k6)
K52
K1 k2 (k22 + 2k2 k3 + k3 2 + k3k4)
C56 = -
K5
A.3 Example 4: Batch Reactor Model
The jacobian matrix is defined by,
G11
G21
G(a)= G31
G41
G51
G12 G13 C14
G22 C23 C24
C32 C33 C34
G42 G43 C44
C52 C53 G54
G15 C16
C25 C26
C35 C36
C45 C46
C55 C56
(A.3)
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The following output was generated using MATHEMATICA,
G11=O
G13=O
G14=1
G15=O
G16=O
0406
G21 = 02 +06
010406
G22 = (02+06)2
G23 = 04
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G24 = 03 + 0106
02 + 06
C25 = 0
010204G26=	 2(02 + 06)
20406 (- (01 02 04) - 0220305 + 01 02 05 06 - 202 0305 06 + 0 1 05 06 2 - 030506)
C31 =
05(02 + 06)
C32 -
01 04 06 (-201 02 04 - 20220305 + 01 0406 + 201 02 05 06 - 402 03 05 06 + 201 05 06 2 - 20305062
05 (02 + 06)
2010406
G33 = 203 04 - _______
U2 + 6
20 1 2 04 06 2	 20120406	 012062	 2010306
G34 = 92 +
05(02+06) - 05(02+06) + (02 +06 ) 2 02 +06
- 0120204206
G35 - 052(02 + 06)
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0 1 0204 (019204 + 20220305 - 201 0496 - 201 02 05 06 + 492939596 - 20105062 + 20305062
G36 = -
05(02 + 06)
C41 0406 (3012022042 + 801 02 030495
 + 30 2 403 2 05 2 - 601 2 92 942 06 - 12012022040506+
160 1 02 2 03 04 05 06 - 601 02 39305 2 06 + 1202 3 93 2 05 2 06 1201 02 0405 06 + 801 02 03 94 05 06 2 +
301 2 02 2 0 5 206 2 - 180192203052062 + 1802 2 03 2 05 2 06 2 + 601 2 02 05 2063 1801 02 0395 2 063 +
1202 03 2 05 2 063 + 301 2 95 2 064 - 60103052064 + 30 20 29 4)/ (92(9 + 06))
C42	 91O4O6 (3920202 + 801 02 0304 O 5 + 392 03 95 - 1001 2 0204 2 06 - 12012022040506+
1201 02 2 03 04 05 06 - 6010230305206 + 1202303205206 + 20 1 2 04 2 06 2 - 801 2 92 94 05 06 2 +
301 2 02 2 95 2 06 2 - 1801 02 2 0305 2 06 2 + 18022032052062 + 40120405063 - 49 1 03 0405 06 +
2 2360 1 2 92 05 2 063 - 18010293952963 + 1202 03 05 V6 + 301 2 05 2 064 - 60103052064 +
303 2 05 2 064) /052(02 + 06)6
G43 —04 (302 303 2 05 - 401 2 02 0406 - 691022030506 + 99220320506 + 30 1 2 02 05 96 2 - 1201020305062.
A.3 Example 4: Batch Reactor Model 	 205
9 0203205062 + 301205063 - 60 1 03 05 96 + 303 2 05 06 3)/05 (02 + 06)
30 1 3 02 042 06 2	 6013042063	 201020406	 2010406	 30130204206
= —03 - ____________ ____________ ___________ ___________ ____________
05 (02 + 06) + 02(0 + 06) + 05 (02 + 06) + 05 (02 + 06) + 05 (02 + 0) -
pii3i2,2	 c)fl3flhjLi2	 3n,3OUi U4 U6
	
bV1 V2U4U6	 "1 23'46	 '1 46
	 '1 '3'4'6
052(02 + 06) - 0 5 (02 + 06 ) - 05 (02 + 06) + 05(02 + 06) - 05 (02 + 06) +
1 234'6	 iv1 416	 '±V1 V3U4V6	 V V6	 0171 346
05 (02 + 06 ) - 05 (02 + 06) - 05(02 + 06) + (02 + 06) + 05(02 + 06) -
301 2 0306 2	 30103206
+(02 +06 )	 02 +06
G45 = _20 1 2 0 2 04 2 06 (0 1 02 04 + 20220305 - 201 04 06 - 201 02 05 06 + 402 03 05 06 - 20105062+
203 05 062 ) /05 (02 + 06)
G46 = 01 02 04 (012022042 + 40 1 02 03 0405 + 302 403 2 05 2 - 80 1 2 02 042 06 - 8012022040506_
6010230305206 + 1202 03 05 06 + 601 2 04 2 06 2 - 1201 02 0304 0 5 06 2 + 301 2 02 2 05 2 062 -
180102203052062 + 18022032052062 + 801 2 0405 063 
- 80 1 03 04 05 06 + 60 1 2 02 05 2 063 -
18010203052063 + 1202032052063 + 301 205 2064 - 60103052064 + 303 2 05 2 06 4) /052(02 + 06)
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G51 = 04 06 (-4G1O204 - 2101 2 02 40304 2 05 - 2201 02 503 2 0405 2 - 4026033053 + 3201302204306+
440130230420506 + 6601 2 024 0304 05 2 06 - 88010240320405206 + 1201 02 5 03 2 05 3 06 -
'- AIl3nLI3n2	 '-n3n2n2LIn2	 2fl2LI,12Lifl224u2 t73 V5 V6 - Ll V2V4 V - lhV l V2 174 175 U6 + 1)0171 72 (73174 56 -
4401302304052062 + 19801 2 023 0304 05 2 062 - 13201 02 3 032 0405 2 06 2 - 1201202403053062 +
	
' i- n i'l 4,i 2j 3 2	 tt-ii 4 n 3n 3j 2	 ,j 3 L jJ 2 j] a 3 i AcLi 2,j LI LI 2 fl /1 3
	
173 175 6	 173 175 6 -
	
'24	 1 '±hV1 234 56 -
3338801302204052063 + 1989 1 2 02 2 0304 05 2 063 - 880102203204052063 + 401 92 05 06 -
A0n21)311Li3113	 o33ii33	 AAI]311111i2114
'01 2 173(75 6 + lhUU l(1 2 (/3 175 6 - 01) 172 (/3 175 6 - '''1 245 6 +
2,i 3n 46601 202 0304 95 2 06 4 - 2291 02 93 2 9405 206 4 + 1201 02 '5 V6 - 7201 2 02 2 03 05 3 96 4 +
120010220 2 3 405 06 - 60022033053064 + 1201 02 05 06 - 480120203053065 +
600102032053065 - 2402 03 05 06 + 401 3 05 3 066 - 1201203053066 + 1201 03 2 05 3 066 -
4033 05 3 06 6) /05 (02
 + 06)
G52 = 01 0406 (-4O1 O204 - 2101 2 02 403 04 2 05 - 2201 02 5 03 2 0405 2 - 4026033053+
4301302204306 + 440130239420596 + 280 1 2 92 3 93 04 2 95 06 + 6601 2 92 403 04 95 2 06 -
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'77I] n 4n 2	 j	 i i'n n 5n 2 3 n	 '-,in 5 3ii 3n	 rzc)1) 3n Li 3n 2( 12 (/3 (/4115 6 1 1L111112 113 115 116 L'±112 113 (15 6 - UZ.V	 24 6 -
4801 30 2 2 94 2 05 06 2 + 1050129220304205062 - 44939399202 + 17601 2 02 3 03 04 05 2 062 -
4 3 3'28801 9 2 3 032 04 05 2 062 - 1201 2 02 4 0305 396 2 + 6001 02 4 932 05 3 062 
- 6002 03 05 6 +
691 04 06 - 7801 3 92 942 05 063 + 4201 2 02 0304 2 05 063 - 7701302204052063 +
33313201 2 022 030 4 0 5 2 063 - 220 1 02 2 03 2 0405 2 063 + 401 02 05 0 - 4801 2 02303053 063 +
12001 023 03 2 0 5 3 063 
- 
8002 03 0 5 06 + 1401 3 042 0 5 064 - 1401 2 0304 2 05 064 -
2201 302 0405 2 06 4
 + 22019203204052064 + 120 1 302 2 05 3 064 - 7201 2 02 2 0305 3964
 +
2j3 3j412001 92 2 0 2 a 3 43 v5 6 - 6092 v3 95
 '-6 + 1191 3 04 05 2 06 5 - 2201 2 9394 95 2 06 5
 +
1101 03 2 04 05 2 06 5
 + 1291 02 05 06 - 480120293053065 + 600 1 02 03 2 95 3 06 5 -
111)31)31)5	 n3n36	 1n2LlLI3n6	 1cni12n3L]6h'±C7 2(73 115 6 + 4vi (/5 6 - 1W1 113115 6 + lhVj(73 (75 V6 -
403 3 053 066) /o(o + 06)8
G53 = 04 (402 5 033 95 2 - 701 392 2 04 2 06 - 2201 2 023 03 9405 06 - 129102403205206+
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2002403305206 + 1401302042062 + 220 1 3 02 2 04 05 06 2 - 44020200002 +
jc,j2/)3flL)2fl2	 Ao1fl3112112L12	 4fl3fl32fl2	 cu13nnnn3ILV1 V2 U3V5 V6 - 'OV1U2 V3 175 6 + '±U172 173 175 V6 + LVl 2456
223220 1 2 02 0304 05 063 
- 40102 05 06 + 3601 2 02 203 05 2 063 - 7201022032052063 +
4002 2 033 05 2 063 - 801 302 05 2 064 + 3601 2 02 0305 2 064 - 480102032052064 +
2002 033 05 2 064 - 4013052065 + 120 1 2 0305 2 06 5 - 1201032052065 +
4033 05 2 06 5 )105 2 (02 +
2 03 05 - 401 02 04 06 - 210 1 3 02 4 0304 2 05 06 - 220120250320405206_G54	 (07 4 3
2 3240 1 02 6033 05 3 06 + 702 6 034 053 06 + 320 1 02 04 6 + 3301402304205062 +
A4L 3 4	 n 2i 2	 2, 4 2	 2fl 2	 ,j 2, 5 2 3n 2
'''1	 173174175	 OOU 2 173 174175 6 + U I/ i V 173 175	 -
'iAflflSLI3fl3LI2	 'iiii433	 -,i4n2n2nn3L'±171172 173 175 6 + h117 2 (/3 175 6 -	 '2'4 6 - :7Ui 2 (74 56 +
i	 2n n 2 n 3	 ')'1L) 4n 3n	 2 3	 1rL) 3 3	 2n 3UJI/[ 2 (73(74	
-	
'1 2 (741/5 6 + lOLL/i 2 173(74175 6 -
1'- n 2 3n 2n n 2n 3	 AL) 3fl 4 1 3I 3	 2j 4fl 2 3n 3	 Lrfl n 4n 3n 3n 3lOhUi 2 (/3 174175 6 - ''i "2 173175 6 + t)U Vi 2 "3 175 6 - UU(/ i (7 2 173 175 V6 +
oL) 4n 411 3n 3	 4(11) 4n ñ 2i1 n 4 i A o l] 3,i n	 21) j 4	 AAL) 4n 2 n 2 4001/2 173	 6 - 'ILl/i 24 56 1 '±L17[ 23"4 56 - ''I '1 2 (/4175 6
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1ocn 3n 2ii n n 2,i 4	 oon 2ii 2n 2ii ii 2n 4	 n 4ii 3n 3n 4	 in 3n 3n n 3n 41OhU1 '2 (73V4U5 V6 - OOV1 '2 (/3 V4V5 6 + 1 2 (/5 6 - 10V1 2 V3V5 6 +
L:n 2,j 3n 2j 3n 4	 Of/I n 3n 3n 3n 4	 ')/) 3ii 4n 3n 4	 41) 1) 1) 2 5UUV V2 (/3 V5 v6 - O UV 1 V 2 (73 (/5	 + t:hiv2 (73 (75 V6 - hhVl v2v4v5 6 +
2 354401 302 03 04 95 2 065_ 2201 2 0203 20405 2 06 5 + 301 02 05 "6 - 2401 302 203 05 306 5 +
6001 2 02 2 03 2 053 06 5 
- 6001 92 2 03305 3 065 + 2102 2 034 053 06 5 + 301 4 02 05 3 066 -
4 f 3,i 6160 1 3 02 0305 306 6 + 3001 2 0203 2 05 3066 - 2401 02 03305 3 066 + 702 03 "5 V6 + 01 05 06 -
2 3e74O1 0305 06 + 601 2 03 05 6 - 401 03 O5 06 + 03 05 06 ) /05 ( 02 + 06)
C55 = 0000 (3012022042 + 1401 02 03 0405
 + 1102 03 2 05 2 - 240120204206_
2201 202 2 04 05 06 - 2201 02 303 05 2 06
 + 4402 303 205 2 06 + 18012042062 + 601 2 92 04 05 06 2 -
4201 02 03 04 05 06 2 +1102 2 02 2 05 2 062 _660102203052062 + 6602 2 03 2 05 2 06 2
 +
280120405063 - 280 1 03 0405 06 + 2201 2 02 05 2 063 - 6601 92 03 05 2 063
 + 4402032052063 +
1101 2 05 2 064
 - 2201 0305 2 06 4
 + 1103 2 05 2 064) /05 (02
 + 06)
C56 = —01 02 04 (91 0204 + 70120240304205 + 1101 02 5 03 2 0405 2 + 4026033053_
A.3 Example 4: Batch Reactor Model	 210
CC)fl 34 2j 3
	
C)flfl 3 3ii 2i
	 Ac)n	 3ai , 2ii n
	 4411 2 4n fl /j 2flhLU1 112 114 116 - Ui	 - 'kLV1 112 '3l4 115116 - ''1 U 113114115
2201 02 4 03 2 04 05 2 06 - 1201 02 5 032 05 3 96 + 2402 03 05 06 + 5801302043062 +
1Afl 3 fl 2 L1 2 flfl2	 1211211fl211112	 rj.-fl3fl3flfl2/2	 0o112113nn121]2U'±V V2 114 115116 - U)V1 112 (/3114	 + 00111 2 114115 6 - 00111 2 1131/4115 6 -
4 3n3,i22201 023 03 2 0405 2 06 2 + 1201 2 02 4 03 05 3 96 2 - 6001024032053062 + 6002 03 V5 V6 -
2401 04 06 + 4401 302 04 205 06 3 + 2801 2 02 03 042 05 063 + 4401 3 92 2 04 05 206 3 -
8801 02 2 03 2 0405 2 063
 - 401 02 5 '6 + 4801 2 923 03 05 3 063 - 1200 1 023 032 05 3 063 +
8002 03 05 06 - 4201304205064 + 420 1 2 0304 2 05 064 - 1101 3 92 04 05 2 064
 +
2348801 2 02 03 04 05 2 064 - 7701 02 03 2 0405 2 064
 - 1201 02 05 06
 + 7201 2 02 2 03 053 064 -
120010220 2 3 43 0 06 + 6002 2 033 05 3 06 4 - 2201 3 04 05 2 065 + 4401 2 0304 05 2 06 5 -
220193204052065 - 129 1 92 05 06 + 4891 2 02 03 05 306 5 - 6001 02 93 2 05306 5
 +
2402 03 05 06 - 4013053066 + 1201 2 03053 066 1201032053066 +
4033 05 3 06 6) 10s(O2 + 06)
